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The objective of this systematic review derived thesis is to present the best available evidence on the 
use of magnesium for neuroprotection during global cerebral ischemia associated with cardiac surgery 
and cardiac arrest in adults. This systematic review utilizes the JBI methodology for quantitative reviews 
presenting JBI level of evidence 1.a (a systematic review of randomised controlled trials). 
The presupposition of this thesis is that for patients who survive global ischemia, improved neurological 
outcome can improve quality of life. This review considered adults above 18 years of age without pre-
existing neurological deficits. The intervention of interest was magnesium administered in doses of at 
least of two grams compared to placebo to adult patients within 24 hours of cardiac arrest or cardiac 
surgery.  
Seven trials were included in this review with 988 participants meeting the inclusion criteria. To enable 
assessment of the available datum, neuroprotection was examined by breaking down neurological 
outcomes into three domains; functional neurological outcomes, neurophysiological outcomes and 
cognitive function.  
The evidence presented in this review highlights the fact that magnesium may provide improved 
functional neurological outcome for patients with global cerebral ischemia. However, current evidence 
does not support the view that magnesium improves long-term cognitive function.  
The individual studies investigating the neuroprotective effects of magnesium during cardiac arrest did 
not show statistical improvement on neurological outcome. Pooled datum using meta-analysis from the 
three trials favored magnesium to improve neurological outcome post cardiac arrest. There was no data 
available for neurophysiological and cognitive function post cardiac arrest.  
For patients post cardiac surgery, there is limited evidence to suggest that magnesium administration 
may improve functional neurological and neurophysiological outcomes. There was no improvement 
noted in cognitive function, where cognitive decline is noted in both placebo and magnesium 
populations.  
This review concludes that research into the neuroprotective properties of magnesium is somewhat 
fragmented, with no standard criteria to assess all of the neurological outcome domains. Future 
research on neuroprotection should involve outcomes from each of the neurological domains, at 

















































































Chapter 1: Introduction 
Chapter introduction 
The focus of this chapter is to provide the context of this thesis, highlighting relevant physiology, 
importance of evidence based health care as a lead in to the presentation of the methods, results and 
discussion of findings from a systematic review. The review focuses on magnesium as a 
neuroprotective agent for populations at risk of global ischemia associated with cardiac arrest and 
cardiac surgery utilizing the methodology of Joanna Briggs Institute (JBI). JBI is a leading international 
organisation for evidence based health care, facilitating the synthesis, transfer and utilization of 
evidence from primary research to clinical practice, in a range of fields including health sciences, 
humanities and social sciences.1 Synthesis through systematic review involves rigorous standardized 
methods to ensure transparency and auditability of the reporting and to enable verification of the results. 
The context of this review is centred on the premise global cerebral ischemia is caused by 
hypoperfusion of the entire brain, resulting in diffuse ischemic injury. Myocardial dysfunction caused by 
cardiac arrest or cardiac surgery resulting in hemodynamic collapse is one of the many causes of global 
cerebral ischemia.2, 3 In an ischemic environment, neurological cellular functions begin to fail within 
minutes, resulting in irreversible pathological damage due to a number of complex biochemical 
processes, (described in detail later).4 Neurological decline is well documented in patients with global 
cerebral ischemia associated with cardiac surgery5-8 and cardiac arrest.2, 9, 10 It is clear that survival is 
not the only important patient outcome, because neurological dysfunction decreases quality of life and 
can increase morbidity and mortality considerably. 
At the time of drafting this thesis, there were no other systematic reviews published that specifically 
focused on addressing the neuroprotective properties of magnesium during global cerebral ischemia 
associated with cardiac arrest and cardiac surgery in humans. Neurological injury due to global cerebral 
ischemia associated with both cardiac surgery and cardiac arrest shares common pathophysiological 
mechanisms, therefore studies from both clinical situations have been included in this review.  
Cardiac surgery 
The risk of global cerebral ischemia related to cardiac surgery is associated with surgical procedures 
requiring iatrogenically induced cardiac arrest,8 and the use of cardiac bypass techniques.7 Cardiac 
bypass, also referred to as a cardiopulmonary bypass, is a technique commonly used for surgeries 
including: coronary artery bypass surgery, aneurysm, valvular and ascending thoracic aortic repair and 
heart transplantations.11 Circulation and tissue perfusion during ‘on pump’ cardiac surgery are 
maintained by extracorporeal cardiopulmonary bypass techniques.11 This procedure involves surrogate 
technology temporarily performing external respiration, oxygenation and circulation of the patients’ 
blood, with redirection of blood from the heart and lungs during surgery.11 Figure 1.1 is a schematic 





Whilst cardiac surgery is often performed to increase quality of life, neurological decline and cognitive 
changes after cardiac surgery have been noted in some patients.12 Cognitive dysfunction is apparent 
in 50% to 80% of cardiac surgery patients at hospital discharge, 20% to 50% at six weeks and 10% to 
30% at six months, post operatively.5 The causes are thought to be multifactorial, including patient 
independent risk factors combined with the sequelae of global cerebral ischemic injury.13 
 
Figure 1.1: schematic representation of cardiopulmonary bypass11 (ALF: arterial line filter, LV: left 
ventricular, K+ cardioplegia solution) 
Cardiac arrest 
Cardiac arrest is the spontaneous cessation of myocardial activity, usually precipitated by cellular insults 
such as hypoxia, toxic injury, metabolic disturbances or trauma. Survival outcomes post cardiac arrest 
are generally very poor.2 For out-of–hospital cardiac arrest, survival (to 28 days) for bystander-
witnessed incidents is 10.6%.14 When cardiac arrest is witnessed by Emergency Medical Services 
(EMS), a 33% survival rate has been reported.14 This data is limited to shockable rhythms only, including 
ventricular fibrillation (VF) or ventricular tachycardia (VT).  Survival rates for in-hospital cardiac arrest 
are slightly higher. The survival rate at hospital discharge increases to between 14% to 32%, depending 
on initial rhythm.15, 16 Patients may survive cardiac arrest due to resuscitation and advanced life support 





full neurological recovery.3, 10 Current estimations suggest only three to seven percent of cardiac arrest 
survivors return to their pre-cardiac arrest level of neurological functioning.10 
Magnesium for neuroprotection 
Several neuroprotective interventions have been investigated for capacity to improve neurological 
outcomes, patient quality of life and reduce morbidity and mortality associated with these conditions.14 
One of these interventions is administration of the endogenous electrolyte, magnesium. Magnesium is 
thought to be beneficial as a neuroprotective agent for global cerebral ischemia due to its multifaceted 
cellular mechanisms, which are described in detail in chapter 2.18 Primary research in this area has 
produced inconsistent results and individual human trials have not reflected the efficacy of magnesium 
for neuroprotection reported in animal trials. This quantitative systematic review analysed randomized 
controlled trials investigating magnesium for neuroprotection during cardiac surgery and cardiac arrest. 
Statement of the review objectives 
The objective of this systematic review was to provide the best available evidence related to the 
neuroprotective effects of magnesium during a period of global cerebral ischemia in adults with cardiac 
arrest or cardiac surgery. Neurological outcomes were examined and an investigation of optimal 






The Joanna Briggs Institute Model of Evidence Based Health Care 
Established in 1996 as a joint initiative of the Royal Adelaide Hospital and the University of Adelaide, 
the JBI has become an international research institute and collaborative venture for evidence based 
health care, with over 70 centres globally.19 The JBI approach considers EBHC to be dependent on the 
evidence as well as the context in which health care is delivered. It is reliant on diverse types of evidence 
(evidence of feasibility, appropriateness, meaningfulness and effectiveness) that are brought together 
after knowledge creation (evidence generation) through synthesis, then transferred to relevant settings 
and implemented within local contexts.19, 20 Global health issues are a driver and reason for evidence 
based health care, and provide the framework for systematic reviews of international literature to inform 
local policy/practice domains; this approach recognises that international evidence is a more robust 
basis for decision making than local knowledge alone, or narrow conceptualisations of evidence. 19, 20 
 
Figure 1.2: The JBI Conceptual Model of evidence based healthcare. 
 
The JBI conceptual model of evidence based health care is presented as an iterative process 
contributing to global health through four major programs: 
I. Evidence generation; 
II. Evidence synthesis; 
III. Evidence (knowledge) transfer; and 
IV. Evidence implementation 
Health care evidence generation begins with gaps in knowledge that are potentially answered by the 
research question.21 Whilst research from well-designed studies is known to be a credible source of 
information, the JBI model recognises that when studies with rigorous methodological study designs 





opinion.21 Evidence is not limited to effectiveness for a specific population. Domains of feasibility, 
meaningfulness and appropriateness are also important in evidence based healthcare, these being 
founded in economics, qualitative inquiry and ethics for healthcare policy and practice.21 
The JBI has three established areas informing evidence synthesis,21 theoretical knowledge, 
methodological development and systematic review methods. This overarching structure of theory, 
methodological development and methods provides the guidance for quantitative, qualitative and mixed 
method systematic reviews.19 Evidence synthesis had traditionally been applied to numerical datum, 
however in JBI, interest in evidence from a wider range of sources has resulted in methodological 
developments for qualitative, economics and other forms of datum synthesis.21 Evidence needs to be 
effectively transferred to the professions to facilitate evidence implementation. Within the model, there 
are three major areas of evidence transfer; education and training; information delivery; and through 
organizational teams.20  
The Evidence Transfer Program in JBI has a focus on pedagogy to increase knowledge, skills and 
capacity for clinicians, academics, researchers and policy makers for evidence based healthcare. 
Evidence implementation is not only dependent on the individual clinicians, policy makers and 
managers of organizations, but also subject to organizational change and practice change, which is 
subsequently evaluated by the impact on patient outcomes.20 
Overview of the science of evidence synthesis 
Evidence based healthcare has been defined as the conscientious use of the current best evidence in 
making decisions about the care of individual patients or delivery of health services and is considered 
fundamental for best practice in clinical practice and policy development.20, 23 For this to happen, gaps 
in knowledge need to be converted into answerable questions.23 As the volume of valid evidence 
increases due to the rapid increase of clinical trials, it is essential that as health professionals we are 
able to assimilate, evaluate and use evidence in the most effective way for patients.24 Systematic 
reviews and evidence-based clinical practice guidelines are methods for assimilating large volumes of 
primary research into synthesized evidence in order to increase the accessibility of research evidence 
and for facilitating the implementation of evidence into practice. It has been suggested that systematic 
reviews be conducted within a broader conceptual framework for evidence based healthcare which is 
focused on implementation. 19, 20 
There are several established centres for evidence based practice that focus on developing evidence 
in the form of systematic reviews covering areas in adult and paediatric medicine, surgery, nursing, 
pharmacotherapy and pathology. The leaders in the global, not for profit EBHC sector include the 
Joanna Briggs Institute,19 the Cochrane Collaboration and Britain’s Centre for Review and 
Dissemination in York.25 This thesis reports the results of a quantitative systematic review informed by 





JBI methodological basis of quantitative systematic reviews  
The Joanna Briggs Institute methodological guidance for the synthesis of primary research into 
systematic reviews has informed the conduct of the systematic review presented in this thesis, albeit 
with some variations to fit the reporting requirements of a conventional thesis.19 The processes and 
steps in the JBI methodology for quantitative systematic reviews are as followed in the JBI Reviewers 
Manual.1 These include: 
I. Formulating the review objective and questions and defining the inclusion and exclusion criteria 
for the review protocol, which is then submitted for review and publication  
II. Searching the evidence  
III. Study selection: based on inclusion criteria as specified in the protocol 
IV. Assessment of identified study quality by critical appraisal using standardized instruments by 
two reviewers 
V. Data extraction, analysis and synthesis 
VI. Drafting the systematic review report 
Formulating the objective and question 
The systematic review process begins with the development of a review protocol based on the review 
question.19 The review question in quantitative reviews of effects is formulated using the mnemonic 
PICO (Appendix 1). The PICO based question is then expanded into a more detailed structure that 
includes detailed description of the relevant characteristics of the Population of interest, the Intervention, 
Control or comparison and Outcomes of interest to the review; in addition to which the preferred study 
designs are described, thus providing clarity to the direction and operationalisation of the review 
question.1  
Data extraction, Analysis & Synthesis 
The JBI SUMARI software (JBI System for the Unified Management, Assessment and Review of 
Information) (Appendix 2) is designed to facilitate each of the seven steps in a quantitative systematic 
review, from question development through comprehensive critical appraisal (Appendix 3), systematic 
data extraction (Appendix 4) and statistical analysis.19 The standardisation of data extraction, analytic 








Definitions of terms 
Cardiac arrest: a sudden, sometimes temporary cessation of cardiac functioning2 
Cardiac surgery: the field of medicine requiring surgical treatment of the organs inside 
the thoracic cavity5 
Functional 
neurological: 
adapted term to describe the branch of neurological outcomes  




hypoxic injury to the entire brain2 
Homogeneity:   studies considered similar enough to be classified together19 
Independent living:   the state of living that does not rely on  others for activities of daily 
living16  
Neurophysiology: the branch of neurological outcomes that is concerned with objective 
physiological measures related to the function of the neurological 
system6 




Any congenital or acquired neurological event or condition that affects 
any aspect of neurological functioning (eg Stroke, Motor Neurone 
Disease, Multiple Sclerosis)5 
 
Cognitive function: the branch of neurological outcomes concerned with emotional 









Quality of life 
Measuring and assessing quality of life raises several challenges. The objective results in quantitative 
trials do not assess the subjective individual perception of outcomes. Health is defined by The World 
Health Organization as “a state of complete physical, mental and social wellbeing, not merely the 
absence of disease”.28  An individual’s quality of life is often multifactorial; it is directly related to their 
perception of their position, received care and directly influenced by culture and beliefs.28 The EQ-5D 
is a standardized instrument to measure quality of life, however this was not directly assessed by the 
studies in this review. For the purpose of this review, quality of life is considered to have declined where 
neurological injury impedes the ability to function independently as measured by functional, 
physiological and cognitive changes. 
Functional neurological outcomes: 
Functional neurological outcomes are assumed in this review to relate specifically to the ability of the 
body to exhibit functional neurological commands. It includes objective assessment of neurological 
function via instruments such as the Glasgow Coma Scale (GCS), Glasgow Outcomes Scale/ Cerebral 
Performance Category, and Karnofsky performance status. Other measures of neurological outcome 
include arousal and consciousness, voluntary controlled movement and co-ordination, and the activities 
of daily living such as the ability to toilet, dress and mobilise. Functional neurological outcome is directly 
related to quality of life, and the ability to perform daily life functions. 
Neurophysiological outcome: 
In the context of this thesis, neurophysiological outcome refers to the results of investigations which 
assess the physiological functioning of the neurological system. These include specific biochemical 
markers and proteins released by neurons, and direct markers of neurological activity. In the included 
trials, the neurophysiological outcomes were neuron specific enolase and P300 evoked potentials.6, 8 
Cognitive function: 
The term cognitive function is usually interchangeable with neuropsychiatric and neurocognitive terms. 
These measure cognitive and behavioural changes with tests including mini mental state examination 
(MMSE), mental state examination (MSE), Hopkins verbal learning test, Controlled Oral Word 
Association Test, Randt Memory Test, Wechsler Adult Intelligence Scale-Revised (WAIS-R) Test, 







Chapter 2: The systematic review protocol 
Chapter introduction 
The review protocol provides an objective a-priori report of the proposed methods and decision-making 
processes within the systematic review. The essential components of the protocol include: the review 
question; the inclusion and exclusion criteria that will be used to select the literature; databases to be 
searched; JBI SUMARI module to be used; type of data extracted and strategies for datum synthesis.19 
The protocol for this systematic review has previously been peer reviewed and published in the Joanna 
Briggs Library of Reviews and Implementation reports.29  
The focus of this chapter is on the presentation of selected existing evidence related to the topic to 
situate the context of the specific review topic within the wider field of study. There are therefore no 
methods specific to this section, and while some animal studies have been included, the overall focus 
is on human studies where in-vitro or in-vivo methods have led to findings that assist in positioning the 
relevance of this systematic review as a contribution to knowledge. 
Background 
Injury caused by global cerebral ischemia during cardiac arrest and cardiac surgery have different 
contributing factors yet both share common pathophysiological mechanisms. Each of these conditions 
has previously been investigated independently due to multiple confounding factors in the setting of 
each of these event and the effect on patient outcomes. The ceassation of myocardial activity is 
predicted and controlled within the cardiac surgery environment under medical guidance,5 in 
comparison with spontaneous cardiac arrest where medical response may be delayed.9 The following 
review of the literature will discuss the current understanding of the pathophysiology of global cerebral 
ischemia, as well as previously investigated neuroprotective therapies used during cardiac surgery and 
cardiac arrest and the current use of magnesium in clinical practice. 
Cardiac surgery 
Cardiac surgery is often performed to increase quality of life for patients with significant cardiac disease 
such as vascular or valvular pathology. However, for patients who suffer complications such as 
cognitive decline or neurologic dysfunction post surgery, quality of life may also decrease post-surgery.7 
Neurologic dysfunction is also associated with a reduction in independent living.5 The most noted type 
of neurological decline is cognitive decline.30  
The mechanisms for neurologic deterioration in the presence of cardiac arrest are similar to vascular or 
valvular pathology, where global cerebral ischemia occurs due to decreased perfusion pressures from 
use of cardiopulmonary bypass techniques or iatrogenically induced cardiac arrest.5, 7, 8 Additional 
factors contributing to ischemia include genetic predisposition, transcerebral platelet activation, cerebral 
embolism, duration of surgery, systemic inflammatory responses, hemodilution, variations in blood 
glucose and fluctuating core body temperature.5 Neurological deficits may include altered 





Perioperative cerebral injury is problematic, contributing to impaired postoperative recovery, increased 
postoperative costs and prolonged hospital stay. 30 Several pharmaceutical strategies have been 
investigated with the objective of reducing the clinical impact of perioperative neurological dysfunction 
and cognitive decline.30 To date, results of these trials have failed to consistently demonstrate effective 
neuroprotective properties.  
Cardiac arrest 
During cardiac arrest, the cessation of organized myocardial activity results in hemodynamic collapse, 
causing hypoperfusion and hypoxia of neuronal cells.5, 31 More than 50% of cardiac arrest survivors 
sustain some degree of permanent cerebral injury, with only three to seven percent of survivors 
returning to pre-arrest level of neurological functioning.10, 32 Cerebral deficits range from memory loss 
and severe depression to brain death and cerebral necrosis, causing significant reduction of quality of 
life.10  
Post cardiac arrest syndrome is the pathology which follows reperfusion after whole body ischemia.3, 33 
The four key sequela of post cardiac arrest syndrome include: post-arrest brain injury; post-arrest 
myocardial dysfunction; systemic ischemia and reperfusion response.3 Precipitating pathology, pre-
existing co-morbidities and duration of arrest also contribute to high morbidity and mortality rates in 
patients with return of spontaneous circulation (ROSC).3, 17 Early mortality is often due to cardiovascular 
instability, whereas late mortality may be associated with cerebral injury. Cerebral dysfunction occurs 
due to a combination of anoxic cerebral conditions and reperfusion injury.3  
The immediate post arrest phase is defined as the first 20 minutes after ROSC. Neuroprotective 
interventions are most effective during the early post arrest phase, occurring between 20 minutes and 
six to twelve hours after ROSC.10 The intermediate phase is between six to twelve hours and 72 hours 
post ROSC. During this phase, injury pathways are still active and are a window where aggressive 
treatment can be initiated.34 
Neurological injury during global cerebral ischemia 
Neurological complications post cardiac surgery and cardiac arrest are common, resulting in 
neurological motor and sensory deficits, altered levels of arousal and consciousness, memory loss, 
depression and cognitive decline.6, 9 As discussed, global cerebral ischemia may result from several 
aetiologies including reduced haemodynamic stability resulting in decreased cerebral perfusion 
pressures from cardiac arrest and certain cardiac surgical procedures.2, 8 Hypoperfusion of the 
cerebrum results in decreased oxygen delivery causing hypoxic ischemic injury.3 For these patients, 
survival is not the only important outcome, since neurological dysfunction impacts on quality of life. 
The pathophysiology of global cerebral ischemia is complex, with much of the physiological knowledge 
originating from studies in animal models. Inflammatory responses and cytotoxic and cerebral oedema 
result in irreversible pathological damage due to a number of biochemical processes,4 including 
glutamate excitotoxicity, calcium dysregulation, and reperfusion injury.35, 36 The neurochemical 





regulation of specific genes, apoptosis and necrosis.37, 38 These processes present clinically with 
neurological dysfunction and psychiatric decline.5 
Glutamate excitotoxicity is central to the pathophysiology of irreversible neuronal damage, resulting in 
calcium and sodium influx via ligand-gated channels causing alterations to the intracellular ionic 
environment.5 Cellular cytotoxic oedema is mediated by an influx of water following sodium and calcium 
ions. The movement of extracellular calcium into the intracellular environment further exacerbates this 
process and initiates apoptotic cascades.39 A subsequent result of hypoxia is anaerobic respiration. 
Secondary lactic acid accumulation and decreased cellular pH triggers lysosomal storage release, 
causing further  cellular necrosis.40 
Glia (neuronal support cells), including astrocytes and microglia, activate as the degree of neuronal 
damage increases. The interplay between cells with the cerebrum further contributes to 
neuroinflammation and neuronal cellular injury. Microglia are the active immunological defence cells of 
the central nervous system which normally protect neurons. During activation, they may inadvertently 
further damage neurons by activation of phagocytic oxidases, release of glutamate, production of 
reactive oxidative species and release of inflammatory cytokines.41  Our understanding of these 
processes from animal models reflect similar processes which occur in humans, providing insights that 







Neuroprotection after global ischemia 
In both cardiac surgery and cardiac arrest, measures to prevent brain injury have been studied, but the 
strategies to minimize brain injury have received less attention.5 Survival outcome research has been 
prioritized over neurological outcome research, influencing research objectives and clinical practice.2 
There is some evidence that hemodynamic optimization, oxygenation and ventilation, circulatory 
support, management of acute coronary syndrome and treatment of the reversible causes (including 
metabolic control) can reduce global ischemia post cardiac surgery and post cardiac arrest neurological 
injury. The International Liaison Committee on Resuscitation recognizes the need to find a 
neuroprotective agent, although to date, there have been few pharmacological measures and clinical 
interventions introduced which elicit neuroprotection.1, 12   
Therapeutic interventions 
Therapeutic interventions for neuroprotection are centred around targeted temperature management, 
maximizing supportive measures, optimising blood glucose and maintaining haemodynamic stability 
and cerebral perfusion pressure. Targeted temperature management, also known as therapeutic 
hypothermia, has been extensively researched and clinical protocols are in place at many institutions. 
Therapeutic hypothermia is hypothesised to reduce cerebral oxygen consumption, thereby suppressing 
the biochemical and metabolic sequelae such as reducing destructive enzymatic reactions and reactive 
free-radical generation. Therapeutic hypothermia is recommended by the American Heart Association 
for patients with ROSC post out-of-hospital cardiac arrest, yet published research on this topic is 
contradictory and therefore inconclusive.42  Some authors suggest therapeutic hypothermia itself may 
not be beneficial, but instead recommend the prevention of spiking fevers to reduce the risk of neuronal 
injury. Evidence supports the use of cooling and antipyretics to maintain normothermia, as each degree 
over 37°C has been correlated to a 2.26 increase in the odds ratio for neurological dysfunction.43 One 
study found that inducing hypothermia (32°C) improved cognitive outcome - measured at one week and 
three months post coronary artery bypass graft surgery - suggesting a benefit of this intervention.44 In 
contrast, others found no adverse effects; intraoperative hypothermia compared to normothermia did 
not improve neurological outcomes; hyperthermia, however, contributed to unfavourable outcomes.45  
Pharmaceutical interventions 
Several pharmaceutical agents have been investigated for potential benefits on neurological outcomes 
post cardiac arrest, including magnesium,9, 16, 31 calcium channel blockers such as lidoflazine,46 
dexmetomidine, erythropoietin, lidocaine30 and glucocorticoids.47 The Brain Resuscitation Clinical Trial 
II46 failed to replicate the neurological benefits of lidoflazine found  in laboratory trials, with several 
complications arising such as hypotension and re-arrest.  
Research into glucocorticosteroids has identified conflicting results. A retrospective study47 found 
administrating glucocorticoids post cardiac arrest did not improve neurological outcome and may be 
associated with additional complications such as increased risk of infection or negative nitrogen 





serological neuron-specific enolase and S100beta protein)48 has been shown to be reduced with 
administration of corticosteroids after cardiac pulmonary bypass. However, a corresponding clinical 
outcome of neurological improvement has yet to be observed.48  
Interventions using dexmedetomidine, erythropoietin and lidocaine have elicited some degree of 
improved neurological outcome, however magnesium appears the safest, with a low risk of harm in 
specific populations.30 The authors of a literature review on neuroprotection after major cardiovascular 
surgery noted that further research is required to determine the safety, efficacy and optimal dosing 
regimens for each of these interventions.30  
Magnesium for neuroprotection 
The neuroprotective mechanisms of magnesium on neurons and glia have been studied in animals 
since the 1980s as they are associated with several physiological processes relevant to cerebral 
ischemia.4,49 These include vasodilatory regulation of cerebral blood flow,6 inhibition of pre-synaptic 
excitotoxic neurotransmitters such as glutamate, mitochondrial stability50 and anti-apoptogenic 
modulation of growth factors.4  
Normal physiological mechanisms of magnesium homeostasis are not yet completely understood. 
Intracellular magnesium in both free and bound forms is essential for the regulation of numerous 
intracellular functions, including enzymes involved in ion channel transport, metabolic cycles and 
signaling pathways. Free magnesium has been shown to diminish during acute and chronic cerebral 
pathologies.51  
Magnesium provides neuroprotection by non-competitive inhibition at post-synaptic glutamate N-methy-
D-aspartate receptors (NMDA), sodium and calcium receptors, thereby inhibiting the release of calcium 
into neuronal cells.6, 52Inhibition of calcium influx reduces glutamate excitotoxicity and calcium 
dysregulation, central to the pathophysiology of cerebral ischemia. Increased intracellular magnesium 
also provides antagonist actions at voltage-gated channels, preventing entry of ions during ischemia 
including calcium, sodium and potassium.4, 52 Figure 2.1 is a schematic representation of where 






Figure 2.1: Schematic representation of the role of magnesium in neuroprotection by NMDA receptor 
inhibition (Adapted from Clinical Anatomy & Neuroscience53)  
 
The normal magnesium plasma and intracellular ranges are 0.70 to 0.85 mmol/L54 and  0.6 mmol/L to 
0.8 mmol/L55 respectively. In normal homeostasis, magnesium is principally absorbed transcellularly 
through the small bowel, with 60-70% of magnesium reabsorption occurring in the ascending loop of 
Henle.56 Cerebrospinal concentrations of magnesium are generally higher at 1.1 mmol/l compared to 
plasma serum concentrations at 0.8 mmol/l.4  
Animal model studies demonstrate cortical extracellular concentrations of magnesium are higher than 
cerebrospinal fluid, indicating active transport across the blood-brain barrier (BBB).18 The 
neuroprotective mechanisms of magnesium in mice are exhibited at physiological extracellular 
concentrations between 250 μmol and 1000 μmol/L.57 These studies have not been replicated in 
humans, and whether these values have a similar effect in humans is unclear. Magnesium transport 
into the cerebral spinal fluid in humans is not yet fully understood, however, current hypotheses include 
transcellular and paracellular mechanisms.18 Initial studies on pre-eclamptic patients receiving 
intravenous magnesium found a modest increase in the cerebral spinal fluid concentrations.57 Both 
intramuscular and intravenous administration of magnesium increase cerebrospinal fluid concentrations 
by 20 to 25%, indicating the possibility of clinically effective therapy.58 
Magnesium for neuroprotection in aligned fields of study 
Focal ischemia associated with acute stroke is most closely aligned to the topic of this review. The 
FAST-MAG trial by Saver et al (2015) investigated the use of magnesium sulphate in patients with acute 
stroke. Whilst the study noted magnesium administration to be safe, no significant shift in the distribution 
of 90-day disability outcomes were measured using the global modified Rankin Scale for the 1700 
patients enrolled.35 Potential physiological explanations for the neutral results (no benefit, no harm) are 





A review suggested the therapeutic role of magnesium in ischemic stroke, intra-cerebral haemorrhage, 
and subarachnoid haemorrhage (SAH) may be limited by late administration.57 In the population with 
SAH, the authors proposed that when the time to magnesium administration was approximately 32 
hours, pathological processes leading to ischemia from vasospasm may have already been 
present.57Clear definitions of “early” as compared with “late” administration are yet to be established, 
although the authors suggested that 32 hours might be too late. Further research into magnesium 
administration at onset of symptoms and throughout recovery is required if a definitive framework for 
“late versus early” is to be established. The authors suggest magnesium has future clinical promise as 
a neuroprotectant therapy, applied to conditions including preterm prevention of intraventricular 
haemorrhage, carotid endarterectomy, cardiac arrest and cardiac surgery. 57  
Research into the neuroprotective properties of magnesium during cardiac surgery has produced 
conflicting results. One trial5 found improved functional neurological outcome in the magnesium group 
compared to placebo at 96 hours (P = 0.0001). Two other trials,6,8  found magnesium did demonstrate 
neuroprotective properties when serum magnesium concentrations were increased. The small sample 
sizes of these studies, n = 288 and n=306, limits the power of these trials. In contrast to these results, 
another trial7 found magnesium did not sustainably improve cognitive function at 6 weeks follow up.  
Clinical trials investigating magnesium for neuroprotection during global cerebral ischemia after cardiac 
arrest have had promising results without adverse effects. One trial31 noted the only participant to 
survive neurologically intact to hospital discharge from a small cohort was from the group who were 
administered magnesium, although it must be acknowledged that this result provides no clear evidence 
of association. Another trial9 found improved functional neurological outcome in their magnesium group 
compared to placebo, three months post arrest.9 A third trial found improved discharge status and 
independent living in the magnesium cohort compared to placebo, post arrest.16 
Current clinical applications of magnesium 
In Australia, magnesium is currently used for pre-eclampsia, eclampsia, preterm labour and acute 
severe asthma.59, 60 Beneficial effects have been reported in cardiovascular diseases,61 including 
unstable angina,62 prolonged QT syndrome and dysrhythmias such as torsades de pointes ventricular 
tachycardia.29 Other current clinical applications of magnesium include correction of hypomagnesia 
associated with digoxin toxicity, hydrofluoric acid poisoning and osmotic laxatives. Magnesium is 
currently an anticonvulsant treatment of choice for women with pre-eclampsia who are at risk of seizures 
to improve maternal and infant outcome and reduce mortality.63 Other, potential therapeutic uses of 
magnesium which are being investigated globally include traumatic brain injury,36, 64 sub-arachnoid 
hemorrhage36, 64 and focal ischemia.36, 64  
The clinical application of antenatal magnesium for neuroprotection of preterm infants has been 
reported to show beneficial neurological outcomes.65, 66 Administration of magnesium sulphate reduces 
the risks of cerebral palsy; the odds ratio ((OR) (OR0.14;95% confidence interval (CI) 0.05 to 0.51)) 





dosing regimen. Due to the lack of recent comparative trials, there is no consensus as to the regimen 
of choice in terms of dose and duration of magnesium.65 
Adverse effects  
The common side effects of hypermagnesia in conscious patients include nausea, flushing and 
vomiting, and, less frequently, headaches and dizziness.59 Initial clinical signs are attributed to 
neuromuscular blockade, including loss of deep tendon reflexes and respiratory depression. Other 
reported effects include thirst, muscle weakness, hypotension, bradycardia, central nervous system 
depression and coma.59 Adverse reactions from high doses are few, however, may include respiratory 
depression and cardiovascular effects such as sinoatrial node blockade, hypotension and circulatory 
collapse.16 
Precautions and contraindications  
Precautions regarding the administration of magnesium are warranted in some conditions such as in 
patients with myasthenia gravis and obstetric patients being treated with nifedipine. Magnesium is 
contraindicated in hypermagnesia or heart block.59 In patients with myasthenia gravis, magnesium 
interferes with neuromuscular transmission, resulting in increased weakness; monitoring of respiratory 
function is required.59 The effects of magnesium may be amplified in the obstetric population treated 
with nifedipine, putting these patients at risk of hypotension and other adverse effects of 
hypermagnesia. Patients with renal impairment may need dose adjustments to prevent hypermagnesia 
because magnesium is predominantly renally cleared.59 
Variations in dosage, time of administration and combination with other therapies contribute to the 
varying results of clinical trials.6 The therapeutic dose of magnesium administered for neuroprotection 
during global cerebral ischemia may be in the range of two to six grams.9, 16, 31, 61  
Quality of life and neurological outcome 
As discussed in chapter one, Quality of life is complex and multifactorial, directly affected by the state 
of health. The effects of neurological dysfunction are apparent in all aspects of health. Several areas of 
life are affected such as the ability to perform activities instrumental to daily living, which in turn affect 
social interaction. Quality of life is subjective to the individual and can be difficult to quantify objectively, 
however is usually evaluated by assessment tools that measure ability to walk and move, as well as 







The necessity of neuroprotective interventions is evident since global cerebral ischemia associated with 
both cardiac surgery and cardiac arrest results in neurological dysfunction. The clinical consequences 
of which may severely impact patients, ranging from functional neurological impediments to cognitive 
decline. Magnesium is a promising neuroprotective agent due to its safety, known adverse effects and 
currently approved applications in clinical practice. The doses required for neuroprotection during global 
cerebral ischemia are similar to those currently administered for pre-eclampsia and eclampsia, 







The objective of this systematic review was to provide the best available evidence related to the 
neuroprotective effects of magnesium during a period of global cerebral ischemia in adults with cardiac 
arrest or cardiac surgery. Neurological outcomes were examined, and an investigation of optimal 
magnesium dosing regimens will also be reported. 
 
Review Questions 
Does therapeutic magnesium admistraion improve neurological outcome in patients with global 
ischemia in the setting of cardiac bypass surgery or cardiac arrest. 
Criteria for considering studies for this review 
The inclusion criteria were formulated using the PICO mnemonic, and published in the a-priori protocol 
as reported in Chapter one (Appendix 1, Table 2.1).67 The pathophysiological mechanisms of global 
cerebral ischemia are similar between cardiac arrest and cardiac surgery, therefore both populations 
were included in this study. The intervention of magnesium administration in either of these conditions 
with measured neurological outcomes was considered in this review.  
Table 2.1: Summary of the PICO used to formulate inclusion and exclusion criteria in the systematic review 
Population Adults at risk of global cerebral ischemia associated with: 
• cardiac arrest, either pre-hospital or the in-hospital setting; or 
• elective cardiac surgery utilizing cardiopulmonary bypass or iatrogenic cardiac arrest 
Intervention Magnesium administration of a minimum 2 g 
Comparison Placebo administration 
Outcome Measurable neurological outcomes 
 
Types of studies 
The primary study designs of interest in this quantitative systematic review were experimental study 
designs including randomized controlled trials, controlled non-randomized trials, and quasi-
experimental trials. In the absence of such trials, this review would also have considered analytical 
epidemiological studies or descriptive study designs. However, the search revealed sufficient 
randomized controlled trials to limit study selection to experimental designs. Study selection was based 
upon initial screening for experimental methods, then detailed reading and checking against the 
inclusion criteria, for whether randomization was reported, and which methods of allocation were 





patient, block, and/or stratified methods. Quasi-randomized trials are those where randomization is not 
truly random but rely on methods that involve sequential allocation. While at a higher risk of allocation 
bias than double blinded trials with truly random allocation, the inclusion of control groups, with “before 
and after” measurement provides suitable baseline data for comparative analysis that is of a higher 
level of evidence than study designs with no controls. Risk of bias was carefully evaluated throughout 
critical appraisal (reported below). 
Types of participants 
This review considered any adults above 18 years of age with global cerebral ischemia who received 
the intervention of interest as described below. Participants may have experienced global cerebral 
ischemia due to cardiac arrest or cardiac surgery. The following exclusion criteria were applied when 
screening the literature. Participants receiving multimodal treatment were excluded from this review. 
Participants were also excluded if there was pre-existing neurological injury or co-morbid conditions. 
Pre-existing neurological deficits were defined as clinical neurological diagnoses or co-morbidities; 
papers were read in detail at study selection to screen out those where the participants had identified 
pre-existing neurological deficits. Additionally, papers were also excluded if neurological outcomes were 
not assessed. 
Types of intervention 
The intervention of interest was magnesium in doses of at least two grams compared to placebo 
administered to adult patients within 24 hours of cardiac arrest or cardiac surgery.9 The immediate effect 
of magnesium for acute emergencies has been demonstrated in current clinical applications such as 
patients with severe asthma or Torsardes de Pointes.59 Ideally, investigation of the immediate 
administration of magnesium would be appropriate for this population. Evidence from Bhudia et 
al(2006)5 and Thel et al (1997)16 suggests magnesium administration up to 24 hours post global 
ischemia is beneficial, therefore the timeframe of 24 hours was chosen to include a wider scope of 
research in this area. Magnesium formulation was not specified in order to incorporate all trials utilizing 
magnesium in this review. The majority of trials use magnesium sulphate, however, other formulations 
have similar clinical effects. 
Types of Comparators 
The comparator to the intervention of interest was passive placebo administration within the same 
timeframe and over the same period as the intervention. All the included trials reported 0.9% Sodium 
Chloride (Normal Saline) as the placebo of choice. 
Types of outcomes 
The primary outcome of interest was neurological status post-cardiac arrest or cardiac surgery as 
measured by objective scales, such as, but not limited to: cerebral performance category, brain stem 
reflex, Glasgow Coma Scale and independent living or dependent living status. Secondary measures 





Neurological outcome  
Neurological assessment is used commonly in both clinical and research practices, however, in this 
review, neuroprotective outcomes were measured differently across the included studies. Accurate 
assessment is essential for long-term and short-term patient outcomes, interventions and assessing 
quality of life, therefore both short-term and long-term assessment were considered for inclusion. 
Several parameters are required to give an overview of neurological function, including independent 
living, communication, motor and sensory function, cognitive and behavioural domains and 
consciousness. The research presented in the included trials tends to only assess selected portions of 
these parameters. To assist in analysing outcomes, neurological outcome has been considered in three 
subsets: functional neurological, neurophysiological and cognitive outcomes. Each of these terms are 
defined in Chapter 1.  
Magnesium dosing regimen 
Magnesium dosing occurred at various time points post cardiac arrest, and pre and post cardiac 
surgery. Investigating patterns of magnesium dosing regimen with neurological outcome will provide 
insight to optimal dosing regimens, including evidence to inform decision making on bolus versus 
infusion for administration. 
Timing of reported neurological outcomes 
The trials included in this systematic review measured neurological outcome at different time points. 
These included 24 hours, three days (72 hours), four days, six weeks, three months and at discharge 




The JBI literature search strategy was applied during this systematic review and included a three-step 
approach. The search strategy attempted to identify all experimental research (randomized controlled 
trials, non-randomized controlled trials, and quasi-experimental reports) relevant to the review question. 
The literature search was completed by the corresponding author.  
A preliminary search using the search terms ‘magnesium’, ‘neuroprotection’, ‘cardiac arrest’, and 
‘cardiac bypass surgery’ was undertaken in the PubMed, EMBASE, CINHAL and Cochrane Central 
Register of Controlled Trials (CENTRAL) databases to identify the database-specific thesaurus and free 
text terms (Appendix 5.1). This was followed by a comprehensive systematic search using appropriate 
indexing terms and medical subject headings specific to each included database. To complete the 
literature search, the reference list of studies meeting the PICO inclusion criteria was screened for 
additional studies. Selected studies for inclusion were critically appraised by two reviewers. 19  
The title and abstract for each article was assessed for eligibility prior to critical appraisal to determine 





alerts were arranged by the corresponding author to ensure new publications meeting the search 
strategy were considered in the review. Only trials published in English were considered for inclusion 
in this review.  
After advice from a librarian, logic grids were used to inform search strategy development for each 
database. Details of the search strategy for published and unpublished trials can be found in Tables 3.2 
and 3.3 respectively. International registers searched for unpublished literature included the Australian 
Clinical Trials Register (www.australianclinicaltrials.gov.au), Australian and New Zealand Clinical Trials 
Register (www.anzctr.org.au), Clinical Trials (https://clinicaltrials.gov/), European Clinical Trials 
Register (www.controlledtrials.com) and ISRCTN Registry (http://www.isrctn.com/). Keywords 
“magnesium” and “neuroprotection” were used when searching these databases (Appendix 5.2). 
Because the clinical implications of magnesium therapy for neuroprotection have been investigated 
since the early 1980s, the search strategy for consideration of inclusion in this review was limited to 
trials published between 1st January 1980 and 1st August 2014. The selected trials were managed using 
EndNote bibliographic software. Duplicates were screed for and removed manually. Only the primary 
reviewer (AP) was involved in selection of the papers (described below), in accordance with the degree 
requirements of the Master of Clinical Science. However, two reviewers were involved in independent 
critical appraisal of the selected papers.  
Study selection 
Article titles and abstracts identified in the search strategy were reviewed to establish whether the paper 
met the inclusion criteria and needed to be retrieved for more detailed reading to confirm relevance and 
applicability through comparison with the inclusion criteria. Papers were selected for review which 
studied adults aged 18 years and older with global ischemia, either by spontaneous or iatrogenic cardiac 
arrest. Participants of the studies needed to receive magnesium within the first 24 hours of arrest and 
have neurological outcome measured. The study selection process followed the PRISMA guidelines 
and reported in figure 3.1, which identifies the number of records retrieved from database searching, 
duplicates and full text eligibility for qualitative synthesis and meta-analysis.68 Included published and 
unpublished trials can be found in Appendix 6 and Appendix 7 respectively. 
 
Assessment of methodological quality and critical appraisal 
Two independent reviewers conducted critical appraisal to assess methodological quality (internal 
validity) of each of the selected trials prior to inclusion, using JBI-MAStARI. JBI-MAStARI includes an 
established critical appraisal tool facilitating assessment of the internal validity, quality and risk of bias 
of the included studies. In the event of disagreements arising between reviewers, a third reviewer was 
available to resolve disagreements. No disagreements occurred between the reviewers.  
The critical appraisal instrument in JBI-MAStARI comprises ten questions, to which possible answers 





randomised control/ pseudo-randomised trials can be found in Appendix 3. This systematic review only 
included RCTs or pseudo RCTs. The review itself was formulated using CReMS software version 5.02.  
Based on the population group studied, a “yes” was required in six out of the ten JBI-MAStARI 
questions. Therefore, trials with a score equal or greater than six out of ten were included in the review. 
Randomization of participants needed to be stated but was not required to be explicitly detailed 
(questions one, three and five). Because of the nature of cardiac arrest, it is not practical to blind 
participants to the intervention (question 2).  It was important the trials had objective measures of 
neurological assessment, measured in a reliable way with the appropriate statistical analysis (questions 
eight, nine and ten). For RCT models, participants of both the control and treatment groups had to be 
treated identically, except for the magnesium intervention. 
 
Datum extraction 
The type of data extracted was predetermined by the protocol.29 Datum was extracted from the trials 
included in this review using the JBI-MAStARI standardized data extraction tool that can be found in 
Appendix 4. The data for each study included the study method, population characteristics and sample 
sizes, study setting and location, interventions used, study outcomes and author conclusions. Datum 
specific to the review question was firstly extracted. The extractions were then reviewed multiple times 
against the original studies to ensure accuracy and reliability of the data. Where sufficient data was not 
available, authors were contacted requesting the primary data. Of the four authors contacted for 
additional details, only one (Professor Fatovich) returned correspondence.  
Datum synthesis 
Quantitative datum from comparable trials was pooled, where possible, in statistical meta-analysis 
using Review Manager 5.3. Effect sizes expressed as odds ratio (for categorical data) and weighted 
mean differences (for continuous data) and their 95% confidence intervals were calculated for analysis. 
Heterogeneity was assessed statistically using the standard chi-square and I2. RevMan 5.3 software 
was chosen for meta-analysis since MAStARI does not report I2, a measure of the consistency between 
trials in meta-analysis.69 The three trials suitable for meta-analysis using this software evaluated 
functional neurological outcomes, post-cardiac arrest.  
The remainder of the trials included in this review had both extensive clinical and methodological 
heterogeneity.67 As statistical pooling was not possible for all outcomes, the findings of heterogeneous 
studies are reported in narrative form, including tables and figures to aid in datum presentation where 
appropriate. Trials were subdivided into categories investigating cardiac arrest and those investigating 
cardiac surgery. Further subdivision of trials includes subcategories of neurological outcomes, 






This review write-up was guided by templates embedded in the JBI software Master of Clinical Science 
students are required to use; the System for the Unified Management, Assessment and Review of 
Information (SUMARI).19 The module of SUMARI applied was the “Meta Analysis of Statistics 
Assessment and Review Instrument” (JBI MAStARI) component. SUMARI includes the Comprehensive 
Review Management System (CReMS) software version 5.03. This software is designed to assist 
researchers to manage and document the steps and phases of the systematic review. Advantages of 
using CReMS software include the programs’ capabilities of incorporating the review protocol, search 
results, review findings, and study characteristics. Additionally, the software is able to create either 
word-rich files or portable document format (PDF). However, Review Manager by the Cochrane 
collaboration was used to facilitate the analysis because it incorporated analytic methods not available 







Chapter 3: Results 
Chapter introduction 
The premise of this review is that for patients who survive global cerebral ischemia, administration of 
intravenous magnesium can improve neurological outcomes. Commencing with a description of the 
included trials, and decisions related to inclusion and exclusion, followed by a critical summary of the 
methodological strengths and weaknesses of the included literature; the “results” chapter then presents 
the key results for the outcome measures that were established a-priori in the published protocol.29 
Description of Studies 
Included trials 
A total of 325 potentially relevant records were identified through database searching; the detailed 
search strategies for each database are reported in Appendix 5. Following the removal of eight 
duplicates, 317 studies were retrieved for examination of title and abstract. A further 291 articles were 
excluded after evaluation of title and abstract for being incongruent with the review inclusion criteria, 
leaving 13 trials for detailed examination. Subsequently, seven full text articles were excluded based 
on evaluation against the appraisal criteria.70-76 During bibliographical review, one additional record was 
identified,31 resulting in seven randomized controlled trials being included for analysis in this systematic 
review (Table 3.1). Four trials investigated magnesium during cardiac surgery (Appendix 6.1) and three 
trials during cardiac arrest (Appendix 6.2). Details of excluded studies are listed in Appendix 7. The 
process of study selection followed PRISMA guidelines68 (Figure 3.1). 
Table 3.1 Potentially relevant records identified by database searching 
Database Search Other resources 
PubMed 28 Australian Clinical Trials Register 0 
 
CINHAL 5 
Australian & New Zealand 
Clinical Trials Register 0 
EMBASE 275 Clinical Trials 1 
CENTRAL 16 European Clinical Trials Register 0 
Total 324 ISRCTN Registry 0 
  Total 1 






After eligibility assessment, seven randomized controlled trials with data from 988 participants in total 
were considered. The outcomes for the methodological quality assessment of the included trials using 
the JBI critical appraisal tool are reported in Table 3.2. Study details of methodological design, including 
neurological outcome measures, timeframes and location, number of participants and mean age, are 
described in Tables 3.3 and 3.4 for cardiac surgery and cardiac arrest respectively.  Prospective 
randomization occurred in four trials which investigated the neuroprotective properties of magnesium 
during elective cardiac surgery.5-8 Patients were randomized during treatment in the three trials 
investigating the neuroprotective properties of magnesium during cardiac arrest.9, 16, 31  
Demographic characteristics of participants were similar among all trials. Included trials were conducted 
in the metropolitan pre-hospital setting,9 hospital emergency department31 or non-emergency hospital 
wards.5-8, 16 The trials were conducted in metropolitan areas with high index of population in the United 
States of America,5, 7, 9, 16 Australia,31 Egypt6 and Austria.8 
It should be noted that the study by Rinosl et al (2013)8 was originally identified as a conference abstract 
paper published in 2009.52 Critical appraisal was conducted on the original conference piece.52 After 
contact with the authors, the outcomes and results presented in the article published in 2013 were 
































Figure 3.1: PRISMA flowchart reporting study management68 
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Methodological quality of included trials 
The seven trials included in this review were critically appraised for methodological quality using the 
JBI-MAStARI critical appraisal tools (Appendix 3). The quality threshold score during critical appraisal 
was six out of ten, including a requirement that the study stated randomization had guided participant 
allocation. Questions requiring “yes” in the JBI-MAStARI critical appraisal tool in order for the study to 
be included were questions six, seven, eight, nine and ten. Trials were required to have the following 
characteristics: 
• To be of RCT design, but not required to specifically state randomization techniques.  
• The magnesium and placebo treatment groups comparable at entry, in terms of disease 
processes and demographic characteristics 
• Participant blinding in the studies of cardiac surgery  
• The magnesium and placebo groups needed to be treated identically except for the named 
intervention  
• The outcomes of participants who withdrew are described and included in the analysis  
• Neurological outcomes were measured in the same ways for participants in the intervention 
and placebo groups  
• Neurological outcomes were measured in reliable ways 
• Appropriate statistical analysis used 
Randomized Controlled Trials (RCT) were the preferred study design for inclusion in this systematic 
review. Evidence of reporting of specific details on the method for patient randomization were preferred 
but not required for inclusion, based on the stated study design. Methods of randomization were well 
described in seven trials. In the remaining trials, randomization methods were not clearly reported.  
Description of allocator blinding was well described in all trials except one.7 This paper was originally 
assessed as a conference abstract, and detailed study methods were not described, hence it was not 
clear whether blinding had been undertaken, and if so, how it had been undertaken. 
Two trials described those assessing outcomes as being blinded to treatment allocation. Trials were 
still included where description of allocator and assessment blinding was insufficient, if the critical 
appraisal score met the threshold.9, 16 The outcomes of people who withdrew during trials were included 
in the analysis in five trials. 5, 7, 9, 16, 31 One trial stated participants did not complete the trial but not 
specifically state reasons of withdrawal.6 The only trial that did not state if participants withdrew was the 
conference abstract.8 The decision to include this study was based on the comparable participant 
number at entry and completion of the study. Based on these criteria, all trials that met the appraisal 
criteria were included in this review. Results of critical appraisal can be found in Table 3.2 and details 






Table 3.2: JBI-MAStARI critical appraisal results of included trials  
Author, date Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 
Rinosl H, Skhirtladze K, 
Birkenberg B, Mora B, 
Steinlechner B & Dworschak M, 
2014 
U Y Y N U Y Y Y Y Y 
Fatovich DM, Prentice DA & 
Dobb GJ, 1997 
Y Y Y Y N/A Y Y Y Y Y 
Thel MC, Armstrong AL, 
McNulty SE, Califf RM & 
O'Connor CM,, 1997 
U Y Y Y Y Y Y Y Y Y 
Hafez HS, Abdelkader AA, 
Elagaty AE, Bakry MA, Nawito 
AM & Elw, 2013 
U Y Y U U Y Y Y Y Y 
Longstreth W, Fahrenbruch C, 
Olsufka M, Walsh T, Copass M 
& Cobb L, 2002 
U Y Y Y Y Y Y Y Y Y 
Mathew HP, White WD, 
Schinderle DB, Podgoreau MV, 
Berger M, Milano C, Laskowitz 
DT, Stafford-Smith M, 
Blumenthal JA ; Newman MF, 
2013 
Y Y U Y N Y Y Y Y Y 
Bhudia S, Cosgrove D, Naugle 
R, Rajeswaran J, Lam B, 
Walton E, Petrich J, Palumbo 
R, Gillinov M, Apperson-
Hansen C & Blackstone E, 
2006 
Y Y Y Y N Y Y Y Y Y 
% 57.14 100.00 85.71 83.33 40.00 100.00 100.00 100.00 100.00 100.00 







Assessment of heterogeneity 
The Joanna Briggs Institute methodological guidance indicates heterogeneity can be attributed to 
clinical, methodological or statistical factors. Clinical heterogeneity is present when there are 
differences in participant characteristics, clinical interventions or how participants were treated in the 
study. Methodological heterogeneity is present when included studies are of varied design or quality, 
while statistical heterogeneity is considered present when variability in summary treatment effects 
between trials is identified.1 Heterogeneity is measured on a scale, and ranges from high to low. Low 
may indicate an absence of heterogeneity, or that while present, it was not significant enough to be 
considered as confounding the results.19  
In this systematic review, demographic characteristics for populations were similar for trials investigating 
cardiac arrest and cardiac surgery. In each study, neurological outcomes were measured reliably, 
participants were treated identically in terms of the type of intervention in either magnesium or placebo 
groups. The homogeneity of populations, treatment/intervention and outcomes measured was the 
premise of the use of meta-analysis in this review for appropriate studies. 
Whilst the overarching principles were similar in all trials, not all measures of neurological outcomes 
were the same. There were variations in the timing of recorded outcomes and dosing regimens. In all 
included studies except one,9 neurological outcomes were measured using validated neurological 
assessment tools in similar populations. To organize the trials based on the assessment outcomes, the 
neurological measures were categorised into functional, physiological and cognitive outcomes. 
Categorization of the trials based on their neurological measure enabled similar trials to be analysed 
using meta-analysis. 
Characteristics and validity of the neurological measurements for cardiac surgery and cardiac arrest 
can be found in Tables 3.3 and 3.4 respectively. Further discussion of the reliability of these assessment 
tools is in Chapter four.  The trial that did not use a validated assessment tool evaluated neurological 
function by living status, and awakening by three months. The Living status categorisation used directly 









Table 3.3 Description of neurological measures and validity of outcomes measured for studies investigating cardiac surgery 
Author, date  Test Category  Neurological measure  Description of Neurological measure Validity 








Score calculated based on the following domains: 
Mentation: 4 tests: level of consciousness, orientation to time, 
place, short term memory & speech 
Motor function: 5 tests limbs, cranial nerves 
Sensory: 4 tests: sensation in R & L upper & lower limbs 
Cerebellar function: 4 tests: movement, gait, reflexes, primitive 
reflexes (glabellar tap, snout response, suck response, 
palmonmental reflex, grasp reflex) 
Validated for neurological assessment in populations at 
risk of stroke during coronary artery bypass surgery.77 
The scale was originally designed to detect and quantify 







Brief assessment of verbal learning, memory, discrimination, 
recognition and recall. 
Studied in populations with vascular dementia and 
Alzheimer’s disease. Validated in populations with 
suspected dementia as a test of learning and memory.78  
Controlled oral word 
association test 
Test of verbal fluency and spontaneous production of words. COWAT 
scores correlate with measures of executive functioning, learning and 
working memory. 
Validated in populations with traumatic brain injury.79 
Some authors are concerned the ability to retrieve words 
is affected by habitual responses.80 
Boston Naming Test Verbalising names in response to visual stimulus. Validated screening tool for cognitive function in 
populations at risk of dementia.81 
Grooved Pegboard & 
digit symbol search 
Visual motor assessment using pegboard and symbol searches. Test 
of executive control capabilities. 
Difference in gender and age noted. Stratified normative 
estimates are required to provide accurate clinical 
assessment.82 






Neuronal response  to an auditory stimulus was calculated by: 
§ The latency: time taken to reach the peak component (in 
milliseconds). 
§ The amplitude: measured in microvolts from the peak of 
the P3 component to the preceding wave. 
P300 cognitive auditory evoked potentials are valid 
measures of cognitive function in populations which 






Table 3.3 continued 




 Cognitive tests comprised of 5 tests to determine score:  
§ Short Story module of the Randt Memory Test   
§ Digit Span subtest of the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R) Test 
§ Modified Visual Reproduction Test from the Wechsler 
Memory Scale 
§ Digit Symbol Test from the Wechsler Memory Scale 
§ Trail making test part B 
Well-validated series of cognitive tests in accordance with 
the Consensus statement on Assessment of 
Neurobehavioural Outcomes after cardiac Surgery.7 






The dominant enolse enzyme found in neural and endocrine 
neuronal tissue. 
Raised concentrations of neuron specific enolase reflects 
proportion of neuronal damage.84 
P300 cognitive 
evoked potentials 
As above As above 
Cognitive Mini-mental State 
Exam 
30-point questionnaire to measure cognitive impairment  The MMSE is a validated clinical and research tool to 
investigate cognitive dysfunction. It cannot be used to make 





Visual motor assessment Validated cognitive assessment tool. Variations in results 
between age and gender, therefore stratified normative 







Table 3.4 Description of neurological measures and validity of outcomes measured for studies investigating cardiac arrest 
Author, date  Test Category Neurological measures Description of Neurological measure Validity 





Glasgow Outcome Scale, 
also known as  the 
Cerebral Performance 
Category (CPC) 
A scale that grades patients’ response to advanced life 
support practices. 
The CPP is a validated  instrument to measure 
outcomes after cardiac arrest.85 







Time to awakening 
Living status 
Awakening, defined as patient having comprehensible 
speech or following commands, and based on the review of 
medical records and telephone contact. 
Living status assessed by 3 months and categorised as 
either neurologically intact (independent) or neurological 
dysfunction (dependent, vegetative or dead).  
No validated objective neurological assessment tool 
used. Datum obtained from audited patient files and 
follow up by direct phone contact  with the patients. 






Glasgow Coma Score 
(GCS) 
 
Practical measure of the conscious state of an individual in 
response to a defined stimuli. Minimum score of 3, 
maximum 15 from 3 domains (eye, voice, motor). 
Validated for predicting mortality but not regarded as a 




A score that measures an individual’s overall performance 
status or ability to perform activities of daily living. Scores 
range from 0 to 100 in increments of 10. 
Validated research tool for neurological assessment.87 
Discharge status: 
Discharge of patient to: 
• Home  self care and independent living 
• Home – assisted care 
• Skilled nursing facility 
No validated objective assessment neurological  tool 






Overview of review findings & main results 
This systematic review included a total of seven trials, randomizing 988 participants. Two trials5, 16 found 
a statistically significant effect of magnesium, three trials7, 9, 31 found no significant statistical difference 
between groups, and the remaining two trials6, 8 noted neuroprotective effects of magnesium during 
administration, with neuroprotective properties decreasing as serum magnesium levels decline.  
Trials were firstly categorized into either cardiac surgery or cardiac arrest. Four trials5,6-8 randomizing 
797 participants investigated the intervention during cardiac surgery and three trials9, 16, 31 randomizing 
191 eligible participants during cardiac arrest. The main results section is then reported across three 
key domains of neuroprotective effects: functional neurological assessment, neurophysiological 
assessment and cognitive assessment. Tables 3.5 and 3.6 describe the results and authors’ 





Neurological outcomes  
Functional neurological outcomes 
Four trials5, 9, 16, 31, 88 including 541 participants assessed functional neurologic outcomes. Functional 
neurological outcome is not limited to arousal or level of consciousness, but also encompasses the 
ability to perform activities of daily living, and independence. For each trial, functional assessment 
varied between Western Perioperative Neurologic Scale (WPNS),5 measured days of awakening and 
independence,9 Glasgow Outcome Scale or Cerebral Performance Category (CPC),31 Glasgow Coma 
Scale (GCS) and Karnofsky performance status.16 
Three5, 9, 16 of the four31 trials that measured functional neurological outcome found improved 
neurological recovery in the magnesium group. Two of these studies were post cardiac arrest9, 16 and 
one, post cardiac surgery.5 The fourth trial,31 also a post cardiac arrest investigation, noted improved 
neurological recovery in several patients from the magnesium cohort, however, these patients did not 
survive to discharge.  
Functional neurological outcomes after cardiac surgery 
One study of 350 participants investigated functional neurological outcome after cardiac surgery.5 This 
study found that maintaining magnesium plasma levels of 3.6 to 4.8 mg/dL was effective in improving 
functional neurological outcome. This was achieved by administering 3.1780mg of magnesium per 
100ml of normal saline. In this trial, data was collected from patients undergoing elective on-pump 
coronary artery bypass grafting (CABG), valve surgery, or combined CABG and valve surgery. 
Functional neurological outcome was measured at 24 hours, 96 hours and psychological data at 3 
months.5 The study utilized scores from the Western Perioperative Neurological scale to measure 
functional neurological outcomes. Neurological assessment was based on the following domains: 
mentation, motor, sensory and cerebella function. Refer to Table 3.4 for further details. 
WPNS scores decreased post-operatively in both groups at 24 hours (p<0.0001). The WPNS score 
coefficient ± standard deviation (SD) was 1.6 ± 0.42. At 96 hours, significant improvement was 
maintained in the magnesium group, which had returned to pre-operative WPNS scores, whereas the 
placebo group did not (p=0.003), with the magnesium group regaining neurological function before the 
placebo group (p=0.01).  
Sensory domain and motor function tests remained relatively unaffected compared to the baseline for 
both magnesium (p<0.3) and placebo (p=0.0) groups. The mentation score returned to pre-operative 
levels in the magnesium group prior to the placebo group, which remained depressed from the baseline 
at 96 hours. Authors were contacted for raw data to enable re-analysis, however, no additional data 
was provided. The placebo group had decreased cerebellar function scores compared to pre-operative 
levels, and increased primitive reflexes (p<0.002). Cerebellar function tests remained at pre-operative 
levels in the magnesium group (p>0.5). The differences between groups for cerebellar function were 





Functional neurological outcomes after cardiac arrest  
Three trials were suited for meta-analysis.9, 16, 31 Dichotomous datum from these three trials investigating 
functional neurological outcome post cardiac arrest by assessing independent living was extracted and 
combined. The rationale for including these studies in meta-analysis was the overarching similar 
characteristics of each study for patients post cardiac arrest. The participants received the intervention 
or placebo as allocated in the protocol and each of the participants had a neurological assessment. 
Each of these trials included neurological assessments categorized as functional neurological 
outcomes for adults, post cardiac arrest.   
There were notable differences in the settings of these three trials. Two trials9, 31 investigated patients 
with out-of-hospital cardiac arrest brought into the emergency department by paramedics, undergoing 
cardio-pulmonary resuscitation. One trial investigated patients with in-hospital cardiac arrest.16 Since 
none of these trials was completed in a critical care environment, each was considered similar in terms 
of environmental capacity. Whilst the magnesium dosing regimen varied in each trial, all three trials met 
the inclusion criteria of a minimum 2g magnesium within 24 hours of cardiac arrest. Although there were 
differences in effect sizes, the outcomes were measured using similar methods and the I2 = 0% indicates 
when pooled, there was low risk of heterogeneity. 
Meta-analysis included 187 participants. In one trial,31 only the eight participants who had neurological 
assessment were included in meta analysis instead of the original 67 participants from this study. Only 
single treatment modes with magnesium were considered, resulting  in 33 participants being included 
from the original 150 participants in another trial.16 Results were analysed using a random effects 
statistical analysis model. The Mantel-Haenszel test for variance was the most appropriate model for 
categorical data with small sample sizes.  
Mantel-Haenszel is the default fixed-effect method of meta-analysis programmed in Review Manager.89 
When datum are sparse, either in terms of event rates being low or study size being small, the estimates 
of the standard errors of the effect estimates that are used in the inverse variance methods may be 
poor. Mantel-Haenszel methods use a different weighting scheme that depends on which effect 
measure (e.g. risk ratio, odds ratio, risk difference) is being used. They have been shown to have better 
statistical properties when there are few events, such as in the case of the included studies. Because 
this is common in Cochrane reviews, the Mantel-Haenszel method is generally preferable to the inverse 
variance method and was applied in this review. In other situations, the two methods give similar 
estimates.89 
Neurological deficits were found to be lower in the magnesium cohort than the placebo participants, 
suggesting magnesium may improve functional neurological outcome, post cardiac arrest (OR 0.44, 
95% CI 0.24-0.81). Individually, studies did not favour magnesium and lacked statistical significance. 
Pooled data in meta-analysis, however, favours magnesium administration to improve functional 






Participants in one study of out-of-hospital cardiac arrest patients brought into the emergency 
department (ED) by paramedics received a 5g magnesium bolus on arrival.31 The outcome of interest 
was the level of neurological intactness as measured by the Glasgow Outcome Scale. Of the 
participants who survived to leave the ED, two of four participants from the magnesium group were 
neurologically intact, whereas one of four of the placebo group participants was neurologically intact. 
An additional two participants from the magnesium group were neurologically intact but did not survive 
to leave the ED, due to septicaemia.31 The second study included a magnesium regimen involving a 2g 
bolus en route to hospital.9 No significant difference (p=0.25) was found between the magnesium 46.7% 
(n=35) and placebo group 37.3% (n=28) in awakening by 3 months. There were significantly higher 
rates of (p=0.05) independent living in the magnesium group at 40%, (n=30) compared to placebo at 
25.3% (n=27.9). At the final three-month assessment, there were no significant differences in 
independence between groups (p=2.9).9 In the final study, the magnesium treatment regimen included 
a 2g bolus followed by an 8g infusion.16 At 24 hours, this study found no significant difference in GCS 
between the magnesium and placebo groups GCS 11 (8-15) and GCS 11 (6-14) respectively. Median 
Karnofsky Performance Status was significantly higher in the magnesium group: 70 (64-80) versus 
placebo: 40 (30-70), (p=0.041). At discharge, the number of participants with independent living was 
significantly higher in the magnesium group at 60% (n=11/16), compared to the placebo group at 35% 
(n=6/17), p=0.052). Comparative description of these results is reported in Table 3.6. 
Neurophysiological outcome after cardiac surgery 
Two studies6, 8 with a total of 58 participants investigated neurophysiological outcomes. Two trials6, 8 
measured  neurophysiology using cognitive P300 evoked potentials and one trial6 assessed 
biochemical measures of neurological damage using neuron-specific enolase (NSE).8 In these studies, 
4mg magnesium was administered shortly after anaesthesia was effective. The effectiveness of the 
intervention declined as serum magnesium levels decreased towards the baseline.8 The limited 
samples sizes of these studies’ trials demonstrates the need for a larger trial.  
In the first study, patients admitted for elective on-pump coronary bypass grafting were administered a 
4g infusion and neurophysiologic testing using cognitive P300 visual evoked potentials at 3 days, 
postoperatively. In the magnesium group, there was a significant decrease in P300 latency post 
operatively, compared to the baseline (preoperative: 449 msec ± 35.87 and postoperative: 404.83 msec 
Figure 3.2: Meta-analysis of trials investigating the neuroprotective properties of magnesium on 





± 49.59; p=0.008) but no difference in amplitude (preoperative: 11.97μv ± 4.48 and postoperative: 
12.55μv ± 3.69; p=0.701), compared to baseline. The placebo group had no significant difference 
between baseline and post-operative latency (preoperatively: 415.6 msec ± 60.77 and postoperatively: 
433.2 msec ± 46.49; p=0.38) or amplitude (preoperatively 9.16 μv ± 3.98 and postoperatively 9.14 μv ± 
4.13; p=0.99). The post operative P300 amplitude was significantly higher in the magnesium group 
compared to the placebo group (magnesium 12.55 msec ± 3.69 versus placebo: 9.14 msec ± 4.13; 
p=0.0241). 
P300 latency evoke potentials were also measured  at three months8. The authors noted an increase 
in latency in both magnesium and placebo groups at three months (magnesium; 459 msec ± 120 versus 
placebo: 410 msec ± 67; p<0.05). The methodological heterogeneity between the two trials, particularly 
the time point for measurement of outcomes, contraindicated meta analysis of these trials. The clinical 
significance of these results are discussed in chapter 5. 
Only one study measured neuron specific enolase (NSE) levels at two, six and 24 hours, post 
operatively.8 NSE remained suppressed post-operatively (10.0μg/L), compared to the baseline 
(9.8μg/L) in the magnesium group. No data was available for comparison from the placebo group, 
however, the authors reported that NSE remained suppressed whilst magnesium remained elevated. 
The authors concluded that treatment with magnesium in this study did not show a clear neuroprotective 
effect, however, serum magnesium >1.2mmol/L temporarily suppressed NSE release from damaged 
neurons. No studies measured neurophysiological outcomes following cardiac arrest, hence reporting 
in this thesis is limited to outcomes following surgery. 
Cognitive outcomes after cardiac surgery 
Three trials8, 13, 52 with a total of 386 patients investigated cognitive outcomes after cardiac surgery. 
Magnesium was not effective in reducing postoperative cognitive decline. Magnesium dosing 
concentrations varied between each of the trials, with one study measuring by weight,7 another study 
administered all patients a 4g bolus followed by 0.6g infusion,8 and the third trial aimed to maintain 
plasma concentrations of 3.6 to 4.8 mg/dL.5 One study had invalid results due to familiarity with testing 
methods resulting in detection bias, and will not be discussed further. 5 
The types of cognitive assessments varied between studies. One study included  a series of five tests 
which provided each participant with an individual score.7 The tests used by this study included the 
Short Story module of the Randt Memory Test, the Digit Span subtest of the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R) Test, the Modified Visual Reproduction Test from the Wechsler Memory 
Scale, Digit Symbol subtest of the WAIS-R,  and the Trail Making Test.7 Another paper performed 
cognitive testing using the mini mental state exam and the forward and backward digit span tests.8 
Table 3.3 and Table 3.4  provide a detailed description of neurological outcomes in cardiac surgery and 
cardiac arrest respectively. 
Results from the final study on cognitive outcomes concluded magnesium administered intravenously 
during cardiac surgery does not reduce postoperative cognitive dysfunction.7 Patients undergoing 





followed by 50mg/kg infusion over three hours. Cognitive assessments were made at 6 weeks. No 
significant difference was found in cognitive tests (p=0.93) or neurocognitive change scores between 
the magnesium and placebo groups (magnesium: 0.07 ± 0.28 versus placebo: 0.13 ± 0.28; p=0.31).   
It should be noted that no studies measured cognitive outcomes following cardiac arrest, hence 
reporting in this thesis is limited to outcomes following cardiac surgery.  
Summary of Results 
A large RCT using the WPNS to measure changes in functional neurological outcomes following cardiac 
surgery found no difference between magnesium and placebo groups for three of the four domains, 
although a positive, persistent change favouring magnesium was noted for cerebellar functioning.5  
Meta-analysis of functional neurological outcomes across three trials of cardiac arrest patients favoured 
intravenous magnesium.9, 16, 31 The analysis was not confounded by heterogeneity, but there were 
inconsistencies in how patients were selected for analysis in two of the three studies, therefore caution 
is needed in interpreting these findings, and further research that adheres to CONSORT requirements 
(including intention to treat analysis) is needed. 
Only two studies investigated neurophysiological outcomes following cardiac surgery, both were limited 
by small sample sizes.6, 8 There were no clinically significant differences between groups, although 
there was a significant decrease in P300 latency associated with magnesium in one study. Neither 
study was able to demonstrate clinical benefit for neurophysiological outcomes following cardiac arrest 
or cardiac surgery. 
In terms of cognitive outcomes following cardiac surgery, three trials with 386 patients were included in 
this review.8, 13, 52 Administration of magnesium was not associated with a protective effect against 
cognitive dysfunction at six week follow-up. There was highly significant heterogeneity between these 
three studies which again highlights the need for research that enables meaningful comparisons 
between studies. Outcomes for each of the included trials are described in  tables 3.5 and 3.6 for cardiac 








Table 3.5: Results for included trials investigating the outcomes of magnesium for neuroprotection during cardiac surgery 
Study Category Neurological measure Time point Results Summary 




Western Perioperative Neurological Scale 24 hours 
 
96 hours 
No significant difference between Mg & placebo 
group (p<0.0001) at 24 hours 
Mg group significantly improved compared to 
placebo (p=0.01) at 96 hours 
No significant difference between Mg & placebo group at 24 hours (p<0.0001) 
Mg group significantly improved compared to placebo at 96 hours (p=0.01) 
Cognitive 
assessment 
Hopkins verbal learning test  
Controlled oral word association test  
Boston Naming Test (BNT)  




Invalid results Conclusion cannot be drawn due to invalid results 




Cognitive P300 Visual Evoked potentials in 
response to stimulus 72 hours Significant difference between Mg & placebo (p=0.0241) 
Evidence of decreased neuron excitability at 3 to 4 days 
Magnesium may have a neuroprotective effect. Neuroprotective effects of 





Short Story module of the Randt Memory Test,  
Digit Span subtest of the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R) Test, 
Modified Visual Reproduction, Digit Symbol subtest 
of the WAIS-R,  and Trail Making Test 
6 weeks No significant difference (p=0.31) 
No significant difference between groups.  Magnesium does not improve 
perioperative cognitive dysfunction 
 





Blood samples: neuron-specific enolase (NSE) 
surrogate marker of neuronal injury 
P300 cognitive evoked potentials 
96 hours 
No significant difference  
(p<0.05) 
No significant difference between groups 
Magnesium temporarily suppresses neurological damage and may have a 
neuroprotective effect. Neuroprotective effects of magnesium evidence whilst 
serum magnesium elevated 
Psychiatric 
assessment 
Mini-mental stae examination 
Digit span test (forward & backward) 
Trail-making test 
3 months Significant decrease in both groups (p<0.05) 





   
Table 3.6: Results for included trials investigating the outcomes of magnesium for neuroprotection during cardiac arrest 
Study Category  24hours Results Summary 




Cerebral Performance Category  
At discharge 
Neurologically 
appropriate: Mg 6.5% 
and Placebo 2.8% 
No significant difference 
between groups (p<0.5) 
At discharge, Neurologically appropriate: Mg 6.5% and Placebo 2.8%. No statistical significant difference 
between groups (p<0.5) 
Only  neurologically intact participant was from magnesium group. 




Awakening at any time by 3 months  
Independent: Measured by 
comprehensible speech, following 
commands and based on medical 
records and telephone contact 
Days to awakening: Calculated by 25% of 
the group awake 
3months 
Increased independent 
living in Mg group 
compared to placebo 
(p=0.05) 
At 3 months, increased independent living in Mg group compared to placebo (p=0.05) 
Magnesium improved functional neurological outcome up to 3 months post arrest however the study 
lacks the power 
Thel et al 199716 
Functional 
assessment 
Median (IQR) Glasgow Coma Score 
(GCS) 
Median (IQR) Karnofsky performance 
status 





No difference in mean 
GCS at 24 hours 
Median KPS higher in Mg 
group (p=0.041) 
Increased independent 
living in Mg group 
(p=0.52) 
At discharge, median Karnofsky performance status significantly higher in Mg group (p=0.041) 
Significantly increased independent living in magnesium group (p=0.52).  Quality of life in cardiac arrest 







Variance in magnesium dosing regimen 
Magnesium treatment regimens varied significantly between included trials (with the exception of those 
studies included in meta-analysis) in terms of both dose and timing of administration. All doses were 
given via the intravenous route. Two trials of cardiac arrest patients included a bolus dose of magnesium 
either enroute9 or on arrival to the emergency department,31 three trials gave a bolus dose followed by 
infusion7, 52,16 and two trials administered an infusion only.5, 6 Dosing regimes are described in detail in 
Table 3.7.  
Magnesium dosing regimen in cardiac surgery 
For patients undergoing cardiac surgery, it is difficult to determine a beneficial pattern from a therapeutic 
dosing regime, in terms of pre-operative magnesium dose, timing and post-operative magnesium 
administration due to the lack of significant findings for most outcomes across the included studies. 
Two trials5, 6 showed significant statistical improvement in functional neurology and physiological 
neurological recovery within two to three days when the first dose of magnesium was administered 
during anaesthesia. The larger trial5 administered 1g magnesium during anaesthesia, followed by a 3g 
infusion over 24 hours; and whilst the second trial6 administered a 4g infusion over 20 minutes. Two 
trials7, 52 found no significant statistical improvement in neurological outcome when magnesium was 
administered during cardiac surgery. Both studies administered a 4g bolus during surgery, followed by 
either a 1g infusion over 2 hours or a 4g infusion over 3 hours. However, questions regarding what the 
optimal dosing regimen remain a research priority. 
Magnesium dosing regimen in cardiac arrest 
For patients in cardiac arrest, the most effective dosing regimen involved 2g magnesium administered 
at the point of ROSC and/or immediately during the post arrest period, followed by a 24-hour infusion. 
Two trials9, 16 found a significant statistical improvement in neurological recovery when magnesium was 
administered during ROSC. No statistical difference in neurological outcomes was recorded in the trial31 






Table 3.7. Magnesium dosing regime 
Author, date Magnesium Route Regimen  Magnesium compound Placebo 
Cardiac Surgery 









Normal saline administered in same 
quantities as magnesium treatment 3.160g Mg/100ml of 
normal saline 
Plasma Mg 3.6 to 4.8 
mg/dL 
IV Infusion 24hours 
Hafez et al 20136 4g Mg  IV Infusion 20 minutes MgSO4 
Normal saline administered in same 
quantities as magnesium treatment 
Mathew et al 20147 
50mg/kg Mg  Bolus 20 minutes after anaesthesia induction 
Not 
specified 
Normal saline administered in same 
quantities as magnesium treatment 5 mg/kg Mg 
(approximately 4.2g for 
an 85kg person) 
IV Infusion 3 hours 
 
Rinosl et al 20138, 52 
 
4g Mg  Bolus 30minutes prior to induction of VF 
MgSO4 
Placebo (n=14) 
Placebo regime not specified 
0.6g  Mg Infusion 2 hours 
Cardiac Arrest 
Fatovich et al 199731 5g Mg in 10ml Bolus On arrival to ED department MgSO4 10ml normal saline bolus 
Longstreth et al 20029 
2g Mg/ 4ml 
2ml normal saline 
 
Bolus En route to hospital MgSO4 
 
4ml Normal saline 
2ml Normal saline 
Thel et al 199716 
 
2g Mg bolus  Bolus At arrest 
MgSO4 
Normal saline administered in same 
quantities as magnesium treatment 
8g Mg IV infusion 24 hours 




 Variance in reporting timeframes between trials of neurological measurement  
Outcomes were measured at various time points for each of the seven included trials. Three 
trials assessed outcomes at 24 hours,5, 8, 16 however only one of these trial16 was included in 
meta-analysis. One trial measured outcomes at six weeks,7 two trials between three to four 
days,5, 6 two trials at three months,5, 9 and two trials at discharge from hospital. There is no clear 
association between outcomes and specific time points of measured neurological outcomes for 
studies investigating either cardiac arrest or cardiac surgery. 
For cardiac surgery, the four included trials measured preoperative baseline levels followed by 
postoperative neurological outcomes, including psychological status, biochemical markers and 
neurophysiological assessment at day three to four. The remainder of the studies had outcome 
measures at 24 hours,5 three to four days,8 six weeks7 and three months.5 For cardiac arrest,  





Chapter 4: Discussion and Conclusions 
Chapter introduction 
Evidence based health care is essential for clinical practice to keep evolving to ensure the best 
outcomes for the patient.23 The Joanna Briggs Institute model of evidence based healthcare 
has established several validated tools for the translation of primary research and clinician 
expertise into knowledge for clinical practice via the synthesis of evidence as systematic 
reviews.20 Neurological assessment is used commonly in both clinical and research practices 
to assess functional staus. Accurate assessment is essential for long-term and short-term 
patient outcomes and interventions. Several parameters are required to give an overview of 
neurological function, including independent living, communication, motor and sensory 
function, cognitive and behavioural domains and consciousness. 
Summary of review protocol 
The study objective 
The objective of this review was to present the best available evidence related to the 
neuroprotective effects of magnesium during a period of global cerebral ischemia associated 
with cardiac arrest or cardiac surgery. Magnesium dosing variances and timeframes were also 
investigated. 
Inclusion criteria 
This review considered adults aged above 18 years. Studies of patients with existing 
neurological deficits or aged below 18 were excluded. Pre-existing neurological deficits were 
defined as diseases or conditions already existing in an individual which would interfere with 
the clinical assessment. The intervention of interest was magnesium administered in doses of 
at least of 2g compared to placebo in adult patients within 24 hours of cardiac arrest or cardiac 
surgery. This review considered experimental designs, including randomized controlled trials, 
non-randomized controlled trials, and quasi-experimental designs.  
The outcome of interest was neurological recovery, post-cardiac arrest or cardiac surgery, as 
measured by objective scales, such as but not limited to cerebral performance category, brain 
stem reflex, Glasgow Coma Score (GCS) and measures of independent living or dependent 
living status. The effect of magnesium on mortality has been extensively studied, therefore 
mortality was not considered an outcome of interest. 
Search strategy 
The search strategy aimed to find both published and unpublished studies between January 
1980 and August 2014 utilizing the Joanna Briggs Institute three-step search strategy. 
Databases searched for published studies included PubMed, EMBASE, CINAHL, Cochrane 
Central Register of Controlled Trials (CENTRAL). Unpublished studies were searched for using 
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Australian Clinical Trials Register, Australian and New Zealand Clinical Trials Register, Clinical 
Trials, European Clinical Trials Register and ISRCTN Registry. 
Data extraction 
Quantitative datum was, where possible, pooled in statistical meta-analysis using the Cochrane 
software Review Manager. Where statistical pooling was not possible, the findings were 
presented in narrative form, including tables and figures, to aid in datum presentation, where 
appropriate. Heterogeneity was noted in neurological outcome measures, magnesium dosing 
regimen and timing of reported neurological outcome, and will be discussed in the following 
section. 
The studies included in this review were critically appraised using the JBI-MAStARI critical 
appraisal tool. Using this tool, all studies met the inclusion threshold of a score of six out of ten. 
Observed differences between trials were identified in population groups, measures of 
neurological outcome, dosing regimens and intervention environments. The populations 
included were similar across the different trials in terms of mean age, and the exclusion criteria 
predominantly including pre-existing neurological injury and multimodal treatments. The studies 
included in this systematic review each investigated neurological outcomes, however, each 
used different definitions, reporting methods and measures of neurological outcome. The 
validity of each of the reported outcomes was assessed (Tables 3.3 and 3.4). 
To understand the causes of heterogeneity, studies were reported based upon populations with 
cardiac arrest, and those with cardiac surgery. There was significant heterogeneity among four 
of the seven studies investigating patients with cardiac arrest, therefore these were analysed 
narratively. Sufficient homogeneity was evident in three studies investigating cardiac surgery 
to perform meta-analysis (I2=0%).  
Neuroprotective effects measured by neurological outcome were categorized into three 
subsets: functional neurological, neurophysiological and cognitive assessment. There is 
significant overlap between these domains, and several neurological measures are likely to be 
used across these three discrete categories. The categorisation of studies was useful to 
understand measured outcomes and clinical implications. Studies investigating neuroprotective 
outcomes post cardiac surgery, included all three domains, whereas only functional 
neurological outcome was assessed in studies that were post cardiac arrest.  
 
Discussion of main results 
Functional neurological outcomes after cardiac surgery 
The data from one trial reporting on neurological outcomes, post cardiac surgery found the 
magnesium group significantly improved 3 to 4 days post surgery compared to placebo when 
maintaining plasma magnesium levels of 3.6 to 4.8 mg/dL for 24 hours, post operatively. Whilst 
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the study power is significant and the study design robust, this data needs to be interpreted 
cautiously. Thee western perioperative neurological scale (WPNS) used to assess neurological 
function has previously only been validated in the setting of pre-operative cardiac patients. The 
WPNS is a tool for preoperative neurological assessment of cardiac patients used clinically in 
North America, with several similarities to clinical neurological examination domains used in 
Australia. Scored tests are used to provide a comprehensive overview of neurological 
assessment, including four main domains: mentation, motor, sensory and cerebellar domains.5 
Details of the WPNS can be found in Appendix 8.1. The nature of the WPNS provides extensive 
insight to functional capacity assessing several domains, including mentation, motor and 
sensory function and primitive reflexes; however, an ideal tool to assess neurological outcome 
in research, however is yet to be validated.90  
Data on the validity of the tool within the literature is limited and has only been referenced in 
the study included. Citation review revealed no insight to the previous use of this tool. The 
authors of this scale were contacted to establish the validity of the tool, however, no response 
was received.5 Issues determining the credibility of this neurological measure are a significant 
barrier to accurately interpreting the results of this trial. 
The addition of magnesium to the intra-operative regimen could potentially improve patient 
recovery. The long-term effects of magnesium administration intra-operatively are yet to be 
established, however the short-term effects have potential benefits. The magnesium group in 
one study was noted to have improved recovery in short-term memory and reduced re-
emergence of primitive reflexes. The outcomes of this study suggest intra-operative elevated 
magnesium levels enable patients to recover more quickly and completely, improving 
neurological recovery. Implementing intra-operative magnesium needs further research to 
determine the efficacy and safety. 
Functional neurological outcomes after cardiac arrest 
Three trials9, 16, 31 measured functional neurological status to investigate the effect of 
magnesium on neurological outcomes during cardiac arrest. The individual studies did not show 
statistical benefit of magnesium administration on neurological outcomes during cardiac arrest. 
However, pooled datum using meta-analysis from the three trials9, 16, 31  favoured magnesium 
to improve neurological outcomes, post cardiac arrest. 
The rationale for including these studies in meta-analysis was the overarching similar 
characteristics of each study for patients post cardiac arrest. The participants received the 
intervention or placebo as allocated in the protocol, and each of the participants included had 
a functional neurological assessment. Whilst different neurological outcome scales were used 
for each trial, each type of measure was concerned with purposeful motor movement, activities 
of daily living and independent living.  
This review concluded that magnesium administration does not improve the survival rate of 
resuscitation,16 therefore advanced resuscitation practices such as advanced airway 
 
 47 
management, compressions and defibrillation should not be delayed for magnesium 
administration.2  The potential benefits of magnesium could easily be incorporated by 
administering supplementation during return of spontaneous circulation (ROSC) care. Since 
the outcomes of patients who suffer cardiac arrest are generally poor, and the safety profile of 
magnesium is strong, this intervention has the potential to improve patient outcome and 
improve functional outcome for those who survive. Further clinical studies are required to 
determine the optimal clinical regimen.  
The administration of magnesium during the ROSC period could be incorporated during fluid 
administration. Electrolyte profiles are regularly monitored in critically unwell patients. 
Magnesium as an additive to fluid sequences could be titrated to maintain the optimum serum 
level. Dosing regimen and optimum serum levels are an area for future research. This would 
influence clinical practice, not only during in-hospital treatment of cardiac arrest, but including 
other areas of healthcare using resuscitation practices such as pre-hospital care. 
One trial measured neurological outcome using the Cerebral Performance Category (CPC) 
(Appendix 8.2) post cardiac arrest.31 This alignes with recommendations by the International 
Liaison Committee on Resuscitation (ILCOR) as part of Utstein data reporting methods.2 This 
five-tier scale incorporates assessment of consciousness and independent status, long-term 
survival and quality of life, post cardiac arrest.92 One trial directly assessed functional living 
status by using discharge destination (nursing home or independent living), the Karnofsky 
performance status (KPS) (Appendix 8.3)  and the Glasgow Coma Scale (GCS) (Appendix 
8.4),16 whilst the other assessed  the ability to perform activities of daily living.9  
The CPC scale has previously been criticised for poorly defined, subjective criteria.91 CPC193 
scores have been found to overestimate patients’ ability, providing inaccurate assessment of 
cognitive and functional neurological outcome. Discrepancies in discharge status have been 
found in patients post cardiac arrest with a CPC 3, who discharged to a range of facilities from 
“home with no services” to long-term acute care”.85 Furthermore, several impairments and 
disability disparate concepts are grouped together, suggesting the need for patient 
subcategories Appendix 9.2. 
Discharge status reflects the individual’s functional status. The facility (home, nursing home) 
patients are discharged to correlates with a measure of independence and therefore functional 
ability. Multiple factors affect discharge status, including insurance coverage,85 family 
members,85 pre-existing morbidity, lower socio-economic status, health literacy and geographic 
location.85  Discharge position correlates poorly with CPC85, indicating future research could 
incorporate discharge status with clinical assessment. This limiting factor reduces the accuracy 
of comparison these two studies. 
The KPS measures the level of care required by assessing the activities of daily living, which 
increase the accuracy of functional status when combined with discharge status.16 This tool is 
currently used in clinical practice to determine the effectiveness of different therapies and 
assess the prognosis of patients with a range of serious diseases such as stroke, cancer and 
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palliative medicine.94 Advantages of the KPS include a comparable measure of functional 
outcome and independence, however, it could also be criticised for subjective clinical 
assessment.95  
The predominant factor limiting comparison of trials during this review was the variances in 
assessment of neurological outcome. The three validated neurological assessment tools are: 
GCS, Canadian Neurological Scale (CNS) and the National Institute of Health Stroke Scale 
(NIHSS). Future research could be centred on recommendations from The National Health and 
Medical Research council of Australia (NHMRC) and aim to use recommendations from the 
expert groups such as the NHMRC and ILCOR when deciding on neurological assessment 
measures.  
 
Neurophysiological outcomes after cardiac surgery 
For the purpose of this systematic review, neurophysiological measures were defined as 
objective measures of changes in physiological functioning. This is an emerging field  which 
does not have the same limitations as functional neurological outcome and cognitive outcome 
measures, which can be unreliable due to subjectivity of the examiner. An objective 
neurophysiological measure such as neuronal activation or a biochemical marker is thus 
justified.  
Neurophysiological datum was obtained from two studies6, 8 using P300 evoked potentials and 
one study8 using neuron specific enolase. Neuron specific enolase (NSE) is a relatively neuron 
specific isoenzyme of enolase, found in the cytoplasm of both neurons and neuroendocrine 
cells.96 During neuronal injury, membrane disruption causes leakage of proteins, including 
NSE, into the extracellular space, which transports to the cerebral spinal fluid (CSF). The CSF 
directly transports components into the venous circulation at the villi of the arachnoid space, 
allowing NSE levels to be directly quantified from plasma samples. 
Reduced NSE levels correlate with reduced neuronal injury. NSE levels are suppressed during 
elevated magnesium serum levels, suggesting magnesium dosing regimen needs to be 
increased and prolonged post operatively to improve neuroprotective effects of magnesium.8 
The clinical implication of maintaining raised serum levels is that it would require prolonged 
magnesium infusion administration. Regular clinical examination and serum electrolyte 
sampling would be required to monitor for side effects associated with raised serum levels.  
Currently in clinical practice, NSE is used to monitor the progress of neural crest tumours, 
including small cell carcinoma of the lung, melanoma, seminoma and neurblastoma.97 Whilst 
testing does not have 100% sensitivity for diagnostic purposes, levels are used to monitor 
response to therapy.98 Conditions resulting in central nervous system disease and damage 
which report increased NSE in the CSF include cardiac arrest, traumatic brain injury, ischemic 
stroke including transient episodes, haemorrhagic stroke, multiple sclerosis and brain 
neoplasms.99 NSE is not routinely measured for these conditions in clinical practice. 
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NSE could potentially be used in the clinical setting of patients with cardiac arrest or cardiac 
injury to monitor neuronal injury. It is known that increased NSE correlates with the degree of 
neuronal damage, yet clinical intervals have not been established in humans. Serum NSE >33 
μg/L in the first three days has been associated with delayed return to consciousness in patients 
who survive cardiac arrest but remain comatose. 100 Further investigation to NSE levels in 
patient with global ischemia is required to assess the reliability of this measure.  
Cognitive P300 evoked potentials are typically used in research rather than clinical practice. 
The voltage and speed of neuronal excitability is measured in response to a direct stimulus, 
producing a waveform that represents the physiological response of neurons in the process of 
decision-making. Results are validated for specifying changes in cognitive function, changes in 
decision-making and alterations in neurotransmitter and electrophysiological abnormalities.101 
Neuron excitability is affected by reduced atrophy, where the degree of structural atrophy 
correlates with reduced neuron excitability.101  Patient factors such as age and pre-existing 
neurological decline would influence the outcome of this measure, and these determinants 
need to be considered prior to further use of this tool.  
Cognitive outcomes after cardiac surgery 
Short-term and long-term neurocognitive decline has been well established after cardiac 
bypass surgery12 and in patients with left ventricular failure.102 Cognitive testing encompasses 
behavioural and psychiatric evaluation. Cognitive decline leading to impaired functioning and 
psychosocial impairments has been documented in patients requiring cardiac surgery and 
following cardiac arrest. Hypoperfusion of the cerebrum had previously been thought to 
contribute to this decline.7  
Several hypotheses for short-term and long-term decline could explain the lack of improvement 
in cognitive outcome. In addition to hypoperfusion of the cerebrum, these reasons could also 
include microemboli, anaesthesia and systemic inflammatory responses.12, 13 Other postulated 
mechanisms include cerebral oxygen desaturation6 and platelet activation.  Cardiac conditions 
are often associated with cerebrovascular pathology due to the similarity of risk factors to 
coronary disease including hypertension, hyperlipidaemia and hypercholesterolemia. In 
addition to the cellular neuroprotective mechanisms, magnesium may improve cerebral blood 
flow via vasodilatory mechanisms.13 
Of the cognitive datum investigated in 3 studies,5, 6, 8 there was no significant difference in 
cognitive function between the magnesium and placebo groups in 2 studies. The results from 
the third study,5 have been omitted from analysis as the data was found to be unreliable. 
Decline in cognitive function has been associated with inadequate serum magnesium levels 
<1.2mmol/L.8 Future trials using adequately powered studies involving prolonged magnesium 
administration could clarify whether there is an association, its strength and direction.  
Inconsistency among cognitive reporting methods has resulted in difficulties in comparing trials. 
Currently, there are numerous cgnitive tests to assess cognitive function. The tests used in this 
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review included a combination of validated tests such as the Randt Memory Test, subsets of 
the digit span test, Mini-Mental State Examination, Weshler Memory Scale and Trail making 
test.6 There is debate among researchers in the field whether future testing should isolate the 
dominant and non-dominant hemispheres. Without consistency in reporting against 
standardised methods, comparisons among research trials will continue to be limited. 
Newer brief cognitive screening instruments used in dementia screening may be useful in 
assessing cognitive decline in patients with global ischemia, due to increased sensitivity and 
specificity. 103 Screening instruments recommended in primary care due to validity and 
reliability, efficacy and sensitivity include the Montreal Cognitive Assessment (MoCA), Mini-
Mental State Examination (MMSE)  Memory Impairment Screen (MIS) and General Practitioner 
Assessment of Cognition (GPCOG).103 Ideally, comprehensive testing involves cognitive, motor 
and perceptual functions including orientation, visual-spatial organisation, executive decision 
making, memory and planning functions such as concentration, attention and comprehension. 
The MMSE is a widely used cognitive screening tool in clinical practice, usage of the MMSE 
has identified several limitations, requiring adjustment for age and education status.103 
Participants with high intelligence or education demonstrate a ceiling effect, leading to false 
negatives.103 False positives occur with increased age, limited education, foreign cultures and 
sensory impairment.103 The MMSE has been criticized for limited sensitivity to frontal and 
subcortical changes, requiring additional testing for frontal and executive function. Yet this tool 
has many advantages, allowing correlation between different population groups and reduces 
administration time. 
Variability in the incidence of cognitive decline could be attributed to numerous factors including 
demographic differences, variance in surgical procedures, study inclusion and exclusion 
criteria, time interval for measuring follow-up, statistical analysis variation and variations in 
control groups.12 Surgical procedural variation reflects differences in technique, which may 
influence cerebral blood flow. These include the cross clamping technique, degree of 
hypothermia, rate of rewarming, and the use of cardiotomy suction.12 The limited control of 
numerous factors contributing to cognitive decline in these patients support the need for long- 
term cognitive follow-up and ongoing support for this patient population.  
For this population, cardiac surgery with implantation of artificial devices reduces cognitive 
decline, supporting the hypothesis of long-term cerebral hypoperfusion.102 Assessing 
neurophysiological decline is difficult due to variations in ischaemic time, variations in cognitive 
assessment and limitations of assessing reperfusion injury.8 A number of these patients have 
arteriosclerosis vascular disease, which potentially will affect cerebral arteries. Vascular 
induced cognitive decline cannot be resolved with a neuroprotective agent administered during 
surgery, but requires a prolonged management plan.  
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Magnesium dosing regimen 
Timing of magnesium dosing 
Magnesium dosing regimen varied significantly between studies. For both cardiac surgery and 
cardiac arrest,  magnesium dosing was most effective when a loading bolus was followed by 
an infusion at the earliest possible point, however, there is not enough evidence in this review  
to make clinical recommendations for the timing of magnesium administration. In the population 
with cardiac surgery, favourable outcomes were observed when magnesium was administered 
during anaesthesia,5, 6 and continued for 24 hours, post procedure.5  
In populations during cardiac arrest, magnesium was most effective during return of 
spontaneous circulation (ROSC)9, 16 not during the resuscitation period. Previous studies31, 104 
have found that administration of magnesium does not reduce mortality during cardiac arrest, 
therefore magnesium administration should not precede normal resuscitation practices such as 
CPR and defibrillation. As discussed earlier, the future clinical application of magnesium 
supplementation could be incorporated as a magnesium additive during fluid resuscitation in 
the early post-arrest period.  
Formulation of magnesium dosing regimen 
For cardiac surgery patients, there is no clear beneficial pattern for magnesium dosing between 
bolus and infusion administration. Two studies reported neurophysiological protection during 
magnesium administration, therefore it may be postulated that prolonged infusion of 
magnesium increases neuroprotection. 6, 8 While another study found the potentially detrimental 
effects of magnesium and slight increase in mortality rate in populations with stroke and 
traumatic brain injury.13  Future research should aim to identify a safe and effective regimen for 
prolong elevated serum magnesium levels post administration. It may be necessary to continue 
magnesium supplementation during the postoperative period. 
In Australia, magnesium treatment is currently indicated for severe asthma, pre-eclampsia, 
eclampsia, neuroprotection for a pre-term foetus less than 30 weeks, some cardiac arrhythmias 
including torsades de pointes and rhythms associated with hypokalemia.59 The dosage of 
magnesium sulphate is highest for pre-eclampsia and eclampsia (4g given over 5 to 10 minutes 
followed by an infusion of 1g per hour for 24 hours). The dose for asthma is diluted to 10mmol, 
approximately 2.5g. 
From the evidence included in this systematic review, we cannot recommend an optimal dosing 
regimen. In the studies presented, the most effective dose of magnesium during cardiac arrest 
was found to be 2g during ROSC, followed by 8g infusion over 24 hours. Further research is 
required to determine the optimal patterns of dosing that could be applied to patients who 
undergo cardiac surgery and cardiac arrest.  
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Adverse effects of magnesium 
The trials included in this review noted the safety of magnesium in doses up to 5g for cardiac 
surgery and 10g for cardiac arrest within a 24-hour period. The adverse events reported in the 
included trials were due to pre-existing co-morbidities and medical complications, not due to 
the magnesium administration.  
Previously reported common adverse effects of magnesium include hypotension, flushing, 
nausea and vomiting.59 More serious effects include bradycardia, central nervous system 
depression and cardiac arrest, although none of these were reported in the included studies. 
The problems in particular for the populations discussed include and increased risk of cardiac 
rhythm disturbances, particular heart block, negative ionotropic effects and concurrent kidney 
injury contributing to the risk of overdose. Continuous clinical monitoring is required in all 
patients with this therapy, in combination with regular clinical examination to detect the effects 





The evidence in this systematic review suggests magnesium administered during anaesthesia 
may provide improved functional neurological outcome for patients with cardiac surgery, 
however, additional studies are required to support this. The neuroprotective effect of 
magnesium occurs while serum levels remain elevated with limited adverse effects. Magnesium 
was not shown to improve long-term cognitive function and cognitive testing has noted a steady 
decline in all intervention and control participants of populations included in this systematic 
review. 
The evidence from this systematic review suggests magnesium administration at the point of 
return of spontaneous circulation (ROSC) after cardiac arrest is effective in improving functional 
neurological outcomes. Further research is required to investigate the optimal dosing regimen, 
however, the most effective formulation used in the trials included in this review was 2g 
magnesium administered during ROSC followed by 8g infusion over 24 hours. Data is not 
available on neurophysiological or cognitive outcomes after cardiac arrest, and is an area for 
future research. 
The limitations of this review are centred around the different measures of neurological 
outcome. Each trial included in this systematic review investigated neurological outcomes, 
however, each trial uses different definitions, reporting methods and measures of neurological 
outcome. Accurate interpretation of the results is difficult in the absence of validated 
comparative data between neurological measures. Congruity of both definitions and 
neurological measures is required among researchers and clinicians to propagate knowledge 
in this area. Currently, terminology and outcome measures are quite different, suggesting the 





Recommendations for clinical practice 
Cardiac Surgery 
Magnesium administration may improve short-term ceebeller functioning in patients who suffer 
global cerebral ischemia associated with cardiac surgery (Grade B) 
Magnesium administration may confer a functional neuroprotective effect in some patients 
whilst serum magnesium levels are elevated (Grade B) 
Magnesium administration does not improve cognitive outcome in patients who suffer global 
cerebral ischemia associated with cardiac surgery (Grade A) 
The optimal dosage, and mode of administration of Magnesium has not been established 
(Grade B) 
Cardiac arrest 
Magnesium administration improves functional neurological outcome in patients who suffer 
global cerebral ischemia associated with cardiac arrest (Grade A) 
Magnesium administration appears to be effective when given as a bolus during return of 
circulation followed by an infusion over 24 hours (Grade B) 
There is insufficient evidence to comment on neurophysiological or cognitive outcomes 
Implications for research 
• Further research is needed in specific domains of functional neurological, 
neurophysiological and cognitive outcomes to determine the effectiveness of 
neuroprotective properties of magnesium during global cerebral ischemia associated 
with cardiac surgery 
• Where possible, researchers should report neurological outcomes using similar 
standards from expert groups such as ILCOR and the NHMRC. Sub categorization of 
measures into functional neurological, neurophysiological and cogntive measures 
allows comparison of studies and comprehensive neurological assessment.  
• Consensus on reporting standards for outcome measurement time points and 
consistent adherence to CONSORT requirements is recommended to enable 






This systematic review critically reviewed and evaluated evidence from experimental studies 
on possible benefits in terms of neuroprotection from intravenous administration of Magnesium. 
The evidence from this systematic review indicates that magnesium may improve functional 
neurological outcomes in some patients who suffer global ischemia associated with cardiac 
surgery and cardiac arrest.  
For patients undergoing elective cardiac surgery, neurophysiological data indicates magnesium 
provides short-term neuroprotection during elevated serum levels with limited adverse effects. 
To date, there are no known additional benefits of magnesium on long-term cognitive function. 
For cardiac arrest patients, magnesium administration offers promise for protection of functional 
neurological outcomes.  
Standardisation of methods, timeframes and adherence to CONSORT requirments in primary 
research are required if future trials are to enable useful comparisons. Researchers should 
consider neurological assessment methods recommended by the NHMRC and ILCO to allow 
comparative research of future trials.  
Future research should incorporate testing of neurological outcome in the domains of functional 
outcome, neurophysiological markers and cognitive tests. Suitable dosing regimens should be 
investigated prior to introduction into clinical practice. Further research is required to investigate 
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Appendix 1: the PICO, PICOH, PICo and SPICE frameworks for developing the 
































P = Problem/ Patient/ Population 
I = Intervention 
C = Control/ Comparison/ Context 
O = Outcomes 
P = Population 
I = Intervention 
P = Professionals 
O = Outcomes 
H = Healthcare setting 
P= Population 
I = Phenomena of Interest 
Co = Context 
S = Setting 
P = Perspective 
I = Intervention 
C = Comparison 










Appendix 2: characteristics of JBI - SUMARI modules QARI, MAStARI, ACTUARI and 
NOTARI1 
Acronym Module Primary research 
designs included 






Qualitative studies Qualitative review Critical appraisal tool 
Data extraction 
Meta-aggregation 





(RCT, pseudo RCT) 
Time series 
Descriptive studies 












Cost benefit or Cost 
utility  
Economic Evaluation Critical appraisal 
Data extraction & 
synthesis of economic 
data 









Appendix 3: Critical Appraisal Instruments  















Appendix 5: Detailed Search Strategy 
 
Appendix 5.1: The search strategy used for published trials  





Heart arrest[mh] OR sudden cardiac death*[tiab] OR out-of-hospital cardiac arrest*[tiab]  
OR 
Resuscitation[mh] OR resuscitation[tiab] OR cardiopulmonary[tiab] advanced cardiac life 
support[tiab] 
OR 
Cardiac Surgical Procedures[mh] OR cardiac surgical procedure* [tiab] OR heart bypass*[tiab] 
OR coronary artery bypass*[tiab] OR cardioplegia[tiab]  
AND 
Magnesium[tw] OR Magnesium compound[mh] 
AND 
Neuroprotective agents[mh] OR neuroprotect*[tw]  
28 
CINHAL 
MH Heart arrest+ OR TI ‘Heart arrest*’ OR AB ‘heart arrest’ OR TI sudden cardiac death* OR 
AB sudden Cardiac death OR TI ‘out-of-hospital cardiac arrest*’ OR AB ‘out-of-hospital cardiac 
arrest’ 
OR 
Resuscitation[mh] OR resuscitation[tiab] OR cardiopulmonary[tiab] advanced cardiac life 
support[tiab] 
OR 
Cardiac Surgical Procedures[mh] OR cardiac surgical procedure* [tiab] OR heart bypass*[tiab] 
OR coronary artery bypass*[tiab] OR cardioplegia[tiab]  
AND 
Magnesium[tw] OR Magnesium compound[mh] 
AND 
MH neuroprotective agents+ OR TI neuroprotect* OR AB Neuroprotect* 
5 
EMBASE 
Resuscitation’/syn OR ‘cardiopulmonary’:ti OR ‘cardiopulmonary’:ab 
OR 
‘sudden cardiac death’:ti OR ‘sudden cardiac death’:ab OR ‘out of hospital cardiac arrest’:ti OR 
‘out of hospital cardiac arrest’:ab 
OR 
’cardiac surgical procedure’:ti OR ’cardiac surgical procedure’:ab R ‘heart bypass’:ti OR ‘heart 
bypass’:ab OR 'coronary artery bypass’:ti OR 'coronary artery bypass’:ab 
AND 
‘magnesium’/syn   
AND 
‘neuroprotection’/syn OR ‘neuroprotective’:ti OR ‘neuroprotective’:ab OR 'neuroprotection':ti 
OR 'neuroprotection':ab  
275 
CENTRAL 
"magnesium" AND "cardiac arrest" 16 




Appendix 5.2: The search strategy used for databases of unpublished trials 






Magnesium AND Neuroprotection 0 
Australia & New 
Zealand Clinical 
Trials Register 
Magnesium AND Neuroprotection 
0 
Clinical Trials Magnesium AND Neuroprotection 1 
European Clinical 
Trials Register 
Magnesium AND Neuroprotection 0 








Appendix 6.1:  Included trials investigating the neuroprotective properties of magnesium during cardiac surgery 
 Population Intervention Comparison Outcomes 
Author, 








Adult patients 18 years 
older admitted for elective 
on-pump cardiac surgery 




12 n=174 n=176 




At 24 hours, No 
significant difference 
between Mg & 
placebo group 
(p<0.0001) 
At 96 hours, Mg group 
significantly improved 
compared to placebo 
(p=0.01) 
Psychiatric Assessment 3 months  
Hafez et al 
20136 
 
Adult patients 18 years 
older admitted for on 
elective on pump cardiac 
surgery (coronary artery 
bypass grafting)  
54 ± 5 n=15 n=15 
Cerebral oximetry 0 hours  
Cognitive P300 evoked 
potentials 3 days 
At 3-4 days, 
Significant difference 





Adult patients 18 years 
older admitted for elective  
cardiac surgery 
68 ± 8 n=198 n=191 Neurocognitive tests 6 weeks 
At 6 weeks, No 
significant difference 
between magnesium 
cohort and placebo 
(p=0.31) 
 
Rinosl et al 
20138, 52 
 
Adult patients 18 years 
older admitted for elective 
cardiac surgery (internal 
cardio/defibrillator 
implantation requiring 
induction of VF) 
60 ± 9 n=14 n=14 
Neuron-specific Enolase 






At 96 hours, No 
significant difference 
between magnesium 
and placebo (p<0.05) 
At 3 months, 
Significant decrease 
in both magnesium 
and placebo  groups 
(p<0.05) 






Appendix 6.2: Included trials investigating the neuroprotective effect of magnesium during cardiac arrest 
 Population Intervention Comparison Outcome 
Author, date Population characteristics Mean Age 
Intervention 




Adult patients 18 years older  
with cardiac arrest.  
Out-of hospital-cardiac 
arrest receiving CPR on 
arrival to ED department 











6.5% and Placebo 





et al 20029 
 
Adult patients 18 years older 
with cardiac arrest 
Out-of-hospital cardiac 
arrest and ROSC achieved 
with minimum systolic blood 
pressure of 90mmHg 
69.2 ± 
14.2  n=75 n=75 
Awakening and lifestyle 
level: (independent, 
dependent, vegetative, 








Thel et al 
199716 
 
Adult patients 18 years older  







GCS 24 hours  
Karnofsky performance 










in magnesium group 
(p=0.52) 






































Appendix 7: Excluded studies  
Table of excluded studies with reasons why they did not meet the inclusion criteria 
Study Reason for exclusion 
Dabbagh et al 201370 Study outcomes were based on post-operative pain, bleeding and extubation time. Neurological 
outcome was not measured.  
Ito et al 201371 Study did not use magnesium during procedure. 
Carrio et al 201272 Study outcomes were based on hours of intubation, cardiac arrhythmias and mortality. Neurological outcome was not measured. 
Aktas et al 200973 Case report using several pharmacological interventions in addition to magnesium. 
Meloni et al 200974 Not primary research. Review article discussing neuroprotection after brain ischemia. 
Iandau et al 200375 Not primary research. Responding letter to original authors Longstreth et al. 
Mohseni et al 201376 Case report using several pharmacological interventions in addition to magnesium. 
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Appendix 8: Details of neurological assessment  
 
 
Appendix 8.1: The Western Neurological Perioperative Scale (WNPS) 
Domain Tests 
Mentation Level of consciousness 
Orientation to time place and person 
Short-term memory 
Speech 
Motor function Motor strength: bilateral upper & lower limbs 
Facial motor strength: cranial nerve testing 
Sensory function Sensation in upper & lower limbs 
Cerebellar function Movement 
Gait 
Reflexes: 
• Upper limb 
• Lower limb 
Primitive reflexes: 
• Glabellar tap 
• Snout response 
• Suck response 
• Palmomental reflex 





Appendix 8.2: The Cerebral Performance Category 
CPC 1 
Good cerebral performance: normal life 
• Conscious, alert, able to work 
• May have minor neurological or psychological deficit including mild 
dysphagia, non incapacitating hemiparesis, minor cranial nerve 
abnormalities 
CPC 2 
Moderate cerebral disability: disabled but independent 
• Conscious, sufficient cerebral function for independent activities of daily life 
• Able to work in sheltered environment 
• May have moderate neurological or psychological impairment including 
hemiplegia, seizures, ataxia, dysarthria, dysphasia and memory changes 
CPC 3 
Severe cerebral disability: conscious but disabled and dependent 
• Conscious but dependent on others for daily support due to limited brain 
function 
• Limited cognition 
• Ranges from ambulatory state to severe dementia or paralysis 
CPC 4 
Com/ vegetative state: Unconscious 
• Unconscious, unaware of surroundings 
• No cognition 
• No verbal or psychological integration with the environment 
CPC 5 
Brain death 
• Certified brain death by traditional criteria 





Appendix 8.3: Australian Modified Karnofsky Performance Status Index 
AKPS Criteria Score 
Normal, no complaints; no evidence of disease 100 
Able to carry on normal activity: minor sign or symptom of disease 90 
Normal activity with effort; some signs or symptoms of disease 80 
Cares for self: unable to carry on normal activity or to do active work 70 
Able to care for most needs; but requires occasional assistance 60 
Considerable assistance and frequent medical care required 50 
In bed more than 50% of the time 40 
Almost completely bedfast 30 
Totally bedfast and requiring extensive nursing care by professionals and/or family 20 






Appendix 8.4 Glasgow Coma Scale 
Behavior Response Score 
Eyes opening Spontaneous 4 
To speech 3 
To pain 2 
No response 1 
Voice Orientated to time, place, person 5 
Confused 4 
Inappropriate words 3 
Incomprehensible sounds 2 
No response 1 
Motor Obeys commands 6 
Moves to localized pain 5 
Flexion withdrawal to pain 4 
Decorticate posturing 3 
Decerebrate posturing  
No response 1 
 
 
